[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGhLf9Dti3ccUG01UC7JSM4jw5fBRnJC0zKvxEzyMiNo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Fox Chase Cancer Center",[4],211,false,45,5,25369,83,[13,16,19,22,24,27,30,33],{"name":14,"count":15},"Lung Cancer",15,{"name":17,"count":18},"Breast Cancer",14,{"name":20,"count":21},"Colorectal Cancer",12,{"name":23,"count":21},"Prostate Cancer",{"name":25,"count":26},"Unspecified Adult Solid Tumor, Protocol Specific",10,{"name":28,"count":29},"Lymphoma",8,{"name":31,"count":32},"Pancreatic Cancer",6,{"name":34,"count":32},"Urothelial Carcinoma",[36,41,46,51,56,60,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03179943","Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma","2020-07-12","Atezolizumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03548961","Organ Preservation in Early Rectal Cancer Patients","2024-04-23","FOLFOX regimen",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05365893","PHL Treatment in Pancreatic Cancer","2025-12-18","Paricalcitol, Hydroxychloroquine, Losartan",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT02755272","A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","2026-05","Pembrolizumab",{"nctId":57,"briefTitle":58,"date":54,"intervention":59},"NCT04506554","A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","AMVAC + Nivolumab",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05274048","Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients","2026-06","Neratinib Pill",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04827810","A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer","2026-06-30","Gamitrinib",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05360732","Redefining FOLFIORINOX in Older Pancreatic Cancer Patients","2026-09-01","FOLFIRINOX",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT05800574","Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer","2026-09-23","Cisplatin",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04055753","Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin\u002FDoxil in Soft Tissue Sarcoma","2026-10-15","Doxil",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,194,269,342,547,581,603,751,845,932,984,1021,1050,1072,1094,1122,1148,1166,1188,1209,1227,1253,1271,1289,1307,1325,1343,1361,1381,1399,1417,1435,1453,1483,1501,1525,1543,1565,1583,1601,1622,1651,1669,1693,1717,1735,1760,1789,1807,1849,1883,1914,1944,1979,2001,2030,2058,2087,2122,2151,2173,2191,2209,2227,2253,2271,2295,2313,2337,2363,2381,2399,2417,2435,2458,2482,2500,2518,2536,2554,2572,2596,2621,2639,2667,2685,2703,2728,2746,2772,2790,2808,2833,2851,2875,2893,2911,2936,2961,2979,3002,3027,3045,3069,3087,3105,3123,3141,3168,3193,3211,3254,3287,3310,3328,3346,3364,3382,3406,3432,3450,3468,3491,3516,3534,3552,3570,3588,3613,3637,3663,3688,3706,3730,3795,3834,3888,3920,3950,3976,4002,4039,4065,4096,4124,4142,4160,4178,4196,4214,4232,4250],{"intervention":55,"totalTrials":94,"cells":95},7,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":115,"PHASE3":188,"PHASE4":190,"NA":192},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":114,"soonestReadout":106},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT07455032","Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas","RECRUITING",[87],"2027-11-30","2028-01-31","2026-04-08",22,[111],"Squamous Cell Carcinoma of Head and Neck",[113,55],"intradermal injection of CADI-05",1,{"trials":116,"activeCount":147,"soonestReadout":54},[117,127,139,153,166,178],{"nctId":52,"briefTitle":53,"status":118,"phases":119,"primaryCompletion":54,"completion":54,"start":120,"enrollment":121,"conditions":122,"interventions":124},"ACTIVE_NOT_RECRUITING",[88],"2016-05-31",87,[123],"Carcinoma Breast Stage IV",[55,125,126],"Carboplatin","Gemcitabine",{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT02939651","A Study of Pembrolizumab in Patients With Neuroendocrine Tumors","COMPLETED",[88],"2018-02","2020-03","2016-10-26",21,[137],"Neuroendocrine Tumors",[55],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":151},"NCT02963610","Phase I\u002FII Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer","TERMINATED",[87,88],"2017-10-03","2018-03-20","2017-03-29",3,[149,150],"Relapsed or Refractory Solid Tumors","Nonsmall Cell Lung Cancer",[152,55],"Lenalidomide",{"nctId":154,"briefTitle":155,"status":118,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":164},"NCT05923190","Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma",[88],"2028-07-01","2029-07-01","2023-06-14",60,[34,162,163],"Metastatic Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma",[165,55],"Enfortumab vedotin",{"nctId":167,"briefTitle":168,"status":104,"phases":169,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":177},"NCT07221942","Pembrolizumab Maintenance After Enfortumab Vedotin (EV)\u002FPembro Induction in Front-Line Metastatic Urothelial Carcinoma",[88],"2028-09-01","2029-09-03","2026-01-23",97,[162,175,176],"Unresectable Urothelial Carcinoma","Advanced Urothelial Carcinoma",[165,55],{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":98,"conditions":186,"interventions":187},"NCT06050954","A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)","WITHDRAWN",[88],"2027-01","2032-01","2023-09",[162],[55,55],{"trials":189,"activeCount":98},[],{"trials":191,"activeCount":98},[],{"trials":193,"activeCount":98},[],{"intervention":195,"totalTrials":9,"cells":196},"Nivolumab",{"EARLY_PHASE1":197,"PHASE1":211,"PHASE2":213,"PHASE3":263,"PHASE4":265,"NA":267},{"trials":198,"activeCount":114,"soonestReadout":203},[199],{"nctId":200,"briefTitle":201,"status":104,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":21,"conditions":206,"interventions":208},"NCT05498792","Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma",[86],"2027-03-04","2027-09-02","2022-11-30",[207],"Locally Advanced or Metastatic Melanoma",[209,210,195],"CBL0137","Ipilimumab",{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":147,"soonestReadout":219},[215,227,238,252],{"nctId":216,"briefTitle":217,"status":118,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT03172754","Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma",[87,88],"2026-11-06","2027-04-06","2017-06-12",98,[224],"Renal Cell Carcinoma",[195,226],"Axitinib",{"nctId":228,"briefTitle":229,"status":142,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":147,"conditions":234,"interventions":236},"NCT03302247","Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy",[88],"2019-03-21","2019-07-12","2018-01-15",[235],"Non Small Cell Lung Cancer Stage IIIB",[195,237],"Nivolumab+Gemcitabine",{"nctId":239,"briefTitle":240,"status":104,"phases":241,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":250},"NCT05263050","Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors",[88],"2026-12","2027-02","2022-01-21",111,[247,248,137,249],"Metastatic Renal Cell Carcinoma","Clear-cell Metastatic Renal Cell Carcinoma","Carcinoid Tumor",[251,195],"Cabozantinib",{"nctId":253,"briefTitle":254,"status":118,"phases":255,"primaryCompletion":242,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT03527108","Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC",[88],"2027-04","2020-10-08",36,[260],"Non Small Cell Lung Cancer",[195,262],"Ramucirumab",{"trials":264,"activeCount":98},[],{"trials":266,"activeCount":98},[],{"trials":268,"activeCount":98},[],{"intervention":126,"totalTrials":9,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":289,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":272,"activeCount":98},[],{"trials":274,"activeCount":98},[275],{"nctId":276,"briefTitle":277,"status":130,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":286},"NCT00761345","Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer",[87],"2014-07","2015-02","2008-09",27,[284,285],"Pancreatic Carcinoma Non-resectable","Metastatic Pancreatic Cancer",[287,288],"gemcitabine","Erlotinib",{"trials":290,"activeCount":147,"soonestReadout":54},[291,295,307,326],{"nctId":52,"briefTitle":53,"status":118,"phases":292,"primaryCompletion":54,"completion":54,"start":120,"enrollment":121,"conditions":293,"interventions":294},[88],[123],[55,125,126],{"nctId":296,"briefTitle":297,"status":142,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT00394147","Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer",[88],"2008-08","2009-12","2006-10",17,[304],"Head and Neck Cancer",[306,287],"pemetrexed",{"nctId":308,"briefTitle":309,"status":104,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT05800587","Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer",[88],"2028-08-01","2029-08-01","2023-02-22",280,[14,316,260],"Small-cell Lung Cancer",[125,318,319,320,321,126,322,323,324,325],"Pemetrexed","Paclitaxel","Nab paclitaxel","Docetaxel","Etoposide","Irinotecan","Topotecan","Lurbinectedin",{"nctId":327,"briefTitle":328,"status":104,"phases":329,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":335},"NCT07043972","Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced\u002FMetastatic Urothelial Carcinoma",[88],"2030-01-01","2031-01-01","2025-07-09",55,[34],[126,125],{"trials":337,"activeCount":98},[],{"trials":339,"activeCount":98},[],{"trials":341,"activeCount":98},[],{"intervention":343,"totalTrials":302,"cells":344},"carboplatin",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":425,"PHASE3":526,"PHASE4":535,"NA":537},{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":98},[349,361,371,386,399,413],{"nctId":350,"briefTitle":351,"status":130,"phases":352,"primaryCompletion":353,"completion":353,"start":354,"enrollment":302,"conditions":355,"interventions":357},"NCT00005021","Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma",[87],"2003-05","1996-07",[28,356,25],"Small Intestine Cancer",[358,343,359,360],"filgrastim","paclitaxel","topotecan hydrochloride",{"nctId":362,"briefTitle":363,"status":130,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":29,"conditions":368,"interventions":369},"NCT00021346","Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors",[87],"2001-07","2002-03","1997-11",[25],[343,370],"gemcitabine hydrochloride",{"nctId":372,"briefTitle":373,"status":130,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":383},"NCT01183559","A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery",[87],"2010-11","2011-08","2008-08-07",9,[380,381,382],"Cancer of the Esophagus","Adenocarcinoma of the Gastroesophageal Junction","Cancer of the Stomach",[384,385,125,319],"Vandetanib","5 Fluorouracil",{"nctId":387,"briefTitle":388,"status":130,"phases":389,"primaryCompletion":390,"completion":390,"start":391,"enrollment":135,"conditions":392,"interventions":396},"NCT01281514","A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer",[87],"2018-01-08","2010-12-14",[393,394,395],"Fallopian Tube Cancer","Peritoneal Cavity Cancer","Recurrent Ovarian Epithelial Cancer",[397,343,398],"everolimus","pegylated liposomal doxorubicin hydrochloride",{"nctId":400,"briefTitle":401,"status":181,"phases":402,"primaryCompletion":403,"completion":404,"enrollment":98,"conditions":405,"interventions":411},"NCT02050009","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[87],"2014-10","2014-10-31",[406,407,408,395,409,410],"Ovarian Papillary Serous Carcinoma","Ovarian Serous Cystadenocarcinoma","Recurrent Fallopian Tube Cancer","Recurrent Ovarian Germ Cell Tumor","Recurrent Primary Peritoneal Cavity Cancer",[412,343,359],"metformin hydrochloride",{"nctId":414,"briefTitle":415,"status":416,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":424},"NCT03094884","Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer","UNKNOWN",[87],"2024-05-01","2025-05-01","2017-02-24",40,[14,423],"Esophageal Cancer",[125,319],{"trials":426,"activeCount":147,"soonestReadout":54},[427,461,476,480,489,500,509,513,517],{"nctId":428,"briefTitle":429,"status":130,"phases":430,"primaryCompletion":431,"completion":144,"start":432,"enrollment":433,"conditions":434,"interventions":458},"NCT01316757","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",[88],"2015-04-07","2011-02-16",24,[435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457],"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary",[459,359,343,460],"cetuximab","erlotinib hydrochloride",{"nctId":462,"briefTitle":463,"status":130,"phases":464,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":473},"NCT02190695","Leukemia SPORE Phase II DAC Study for R\u002FR and Elderly Acute AML and MDS",[88],"2018-06-26","2020-04-16","2013-04-01",92,[470,471,472],"Acute Myeloid Leukemia","Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia",[474,125,475],"Decitabine","Arsenic trioxide",{"nctId":52,"briefTitle":53,"status":118,"phases":477,"primaryCompletion":54,"completion":54,"start":120,"enrollment":121,"conditions":478,"interventions":479},[88],[123],[55,125,126],{"nctId":481,"briefTitle":482,"status":130,"phases":483,"primaryCompletion":484,"completion":132,"start":485,"enrollment":486,"conditions":487,"interventions":488},"NCT00043108","Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer",[88],"2016-12","2002-07",19,[14],[343,359],{"nctId":490,"briefTitle":491,"status":130,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":147,"conditions":496,"interventions":498},"NCT00003944","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[88],"1999-12","2003-02","1998-08",[393,497,394],"Ovarian Cancer",[358,343,499,359,360],"cyclophosphamide",{"nctId":501,"briefTitle":502,"status":130,"phases":503,"primaryCompletion":504,"completion":494,"start":505,"enrollment":147,"conditions":506,"interventions":508},"NCT00003943","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.",[88],"2000-11","1998-09",[507,14],"Carcinoma of Unknown Primary",[358,343,499,359,360],{"nctId":308,"briefTitle":309,"status":104,"phases":510,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":511,"interventions":512},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"nctId":327,"briefTitle":328,"status":104,"phases":514,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":515,"interventions":516},[88],[34],[126,125],{"nctId":518,"briefTitle":519,"status":181,"phases":520,"primaryCompletion":521,"completion":521,"enrollment":98,"conditions":522,"interventions":524},"NCT00021307","Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme",[87,88],"2002-04",[523],"Brain and Central Nervous System Tumors",[343,525],"temozolomide",{"trials":527,"activeCount":98},[528],{"nctId":529,"briefTitle":530,"status":181,"phases":531,"primaryCompletion":532,"completion":532,"start":532,"enrollment":98,"conditions":533,"interventions":534},"NCT00054392","Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",[89],"2001-09",[14],[343,370,359],{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":98},[539],{"nctId":540,"briefTitle":541,"status":130,"phases":542,"primaryCompletion":543,"completion":544,"start":420,"enrollment":32,"conditions":545,"interventions":546},"NCT03095209","Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery",[],"2019-11-20","2021-01-18",[14,423],[125,319],{"intervention":40,"totalTrials":548,"cells":549},2,{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":575,"PHASE4":577,"NA":579},{"trials":551,"activeCount":98},[],{"trials":553,"activeCount":98},[],{"trials":555,"activeCount":548,"soonestReadout":39},[556,568],{"nctId":557,"briefTitle":558,"status":118,"phases":559,"primaryCompletion":242,"completion":560,"start":561,"enrollment":562,"conditions":563,"interventions":565},"NCT03125928","Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",[88],"2027-12","2017-06-13",16,[564],"HER2-positive Breast Cancer",[40,319,566,567],"Trastuzumab","Pertuzumab",{"nctId":37,"briefTitle":38,"status":118,"phases":569,"primaryCompletion":39,"completion":570,"start":571,"enrollment":135,"conditions":572,"interventions":573},[88],"2022-07","2017-11-27",[34],[40,574],"Guadecitabine",{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":98},[],{"trials":580,"activeCount":98},[],{"intervention":165,"totalTrials":548,"cells":582},{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":548,"soonestReadout":157},[589,593],{"nctId":154,"briefTitle":155,"status":118,"phases":590,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":591,"interventions":592},[88],[34,162,163],[165,55],{"nctId":167,"briefTitle":168,"status":104,"phases":594,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":595,"interventions":596},[88],[162,175,176],[165,55],{"trials":598,"activeCount":98},[],{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":98},[],{"intervention":359,"totalTrials":604,"cells":605},20,{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":626,"PHASE3":737,"PHASE4":743,"NA":745},{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":98},[610,614,618,622],{"nctId":350,"briefTitle":351,"status":130,"phases":611,"primaryCompletion":353,"completion":353,"start":354,"enrollment":302,"conditions":612,"interventions":613},[87],[28,356,25],[358,343,359,360],{"nctId":372,"briefTitle":373,"status":130,"phases":615,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":616,"interventions":617},[87],[380,381,382],[384,385,125,319],{"nctId":400,"briefTitle":401,"status":181,"phases":619,"primaryCompletion":403,"completion":404,"enrollment":98,"conditions":620,"interventions":621},[87],[406,407,408,395,409,410],[412,343,359],{"nctId":414,"briefTitle":415,"status":416,"phases":623,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":624,"interventions":625},[87],[14,423],[125,319],{"trials":627,"activeCount":548,"soonestReadout":242},[628,632,636,640,644,656,660,674,684,694,698,709,719,727],{"nctId":428,"briefTitle":429,"status":130,"phases":629,"primaryCompletion":431,"completion":144,"start":432,"enrollment":433,"conditions":630,"interventions":631},[88],[435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457],[459,359,343,460],{"nctId":557,"briefTitle":558,"status":118,"phases":633,"primaryCompletion":242,"completion":560,"start":561,"enrollment":562,"conditions":634,"interventions":635},[88],[564],[40,319,566,567],{"nctId":481,"briefTitle":482,"status":130,"phases":637,"primaryCompletion":484,"completion":132,"start":485,"enrollment":486,"conditions":638,"interventions":639},[88],[14],[343,359],{"nctId":490,"briefTitle":491,"status":130,"phases":641,"primaryCompletion":493,"completion":494,"start":495,"enrollment":147,"conditions":642,"interventions":643},[88],[393,497,394],[358,343,499,359,360],{"nctId":645,"briefTitle":646,"status":130,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":654},"NCT00350025","Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer",[88],"2010-07","2012-09","2006-08",41,[653],"Urologic Neoplasm",[655,319],"Cetuximab",{"nctId":501,"briefTitle":502,"status":130,"phases":657,"primaryCompletion":504,"completion":494,"start":505,"enrollment":147,"conditions":658,"interventions":659},[88],[507,14],[358,343,499,359,360],{"nctId":661,"briefTitle":662,"status":130,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":147,"conditions":667,"interventions":668},"NCT00003957","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",[88],"2000-09","2001-08","1998-12",[28],[358,669,499,670,671,672,673,359],"recombinant human stem cell factor","cytarabine","etoposide","melphalan","mitoxantrone hydrochloride",{"nctId":675,"briefTitle":676,"status":142,"phases":677,"primaryCompletion":678,"completion":678,"start":679,"enrollment":604,"conditions":680,"interventions":682},"NCT05420636","Iadademstat in Combination With Paclitaxel in Relapsed\u002FRefractory SCLC and Extrapulmonary High Grade NET",[88],"2025-07-23","2022-12-21",[316,681],"Neuroendocrine Carcinoma",[683,319],"Iadademstat",{"nctId":685,"briefTitle":686,"status":142,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":21,"conditions":691,"interventions":692},"NCT01962948","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[87,88],"2016-05-09","2018-07-06","2013-10-09",[408,395,410],[359,693],"ganetespib",{"nctId":308,"briefTitle":309,"status":104,"phases":695,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":696,"interventions":697},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"nctId":699,"briefTitle":700,"status":130,"phases":701,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":707},"NCT00021333","Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer",[88],"2006-04","2008-05","1999-09",29,[304,14],[358,708,359],"cisplatin",{"nctId":710,"briefTitle":711,"status":130,"phases":712,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":717},"NCT00021372","Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[88],"2006-09","1996-02",25,[28],[718,359],"estramustine phosphate sodium",{"nctId":720,"briefTitle":721,"status":181,"phases":722,"primaryCompletion":723,"completion":723,"start":724,"enrollment":98,"conditions":725,"interventions":726},"NCT00084565","Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer",[88],"2004-11","2003-11",[23],[718,359,360],{"nctId":728,"briefTitle":729,"status":130,"phases":730,"primaryCompletion":731,"completion":732,"start":733,"enrollment":135,"conditions":734,"interventions":735},"NCT00021320","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer",[88],"2004-01","2009-04","2000-05",[423],[708,736,359],"fluorouracil",{"trials":738,"activeCount":98},[739],{"nctId":529,"briefTitle":530,"status":181,"phases":740,"primaryCompletion":532,"completion":532,"start":532,"enrollment":98,"conditions":741,"interventions":742},[89],[14],[343,370,359],{"trials":744,"activeCount":98},[],{"trials":746,"activeCount":98},[747],{"nctId":540,"briefTitle":541,"status":130,"phases":748,"primaryCompletion":543,"completion":544,"start":420,"enrollment":32,"conditions":749,"interventions":750},[],[14,423],[125,319],{"intervention":708,"totalTrials":378,"cells":752},{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":781,"PHASE3":839,"PHASE4":841,"NA":843},{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[757,765,772],{"nctId":758,"briefTitle":759,"status":130,"phases":760,"completion":761,"start":494,"conditions":762,"interventions":763},"NCT00062322","Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer",[87],"2009-10",[14],[708,764],"irinotecan hydrochloride",{"nctId":766,"briefTitle":767,"status":130,"phases":768,"primaryCompletion":713,"completion":713,"start":769,"conditions":770,"interventions":771},"NCT00022308","Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer",[87],"1999-01",[14],[708,764],{"nctId":773,"briefTitle":774,"status":130,"phases":775,"primaryCompletion":493,"completion":504,"start":776,"enrollment":32,"conditions":777,"interventions":779},"NCT00003263","Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma",[87],"1996-08",[778],"Malignant Mesothelioma",[780,708],"recombinant interferon alfa",{"trials":782,"activeCount":114,"soonestReadout":78},[783,799,808,815,819,835],{"nctId":784,"briefTitle":785,"status":130,"phases":786,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":793},"NCT02710734","Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)",[88],"2025-11-27","2025-12","2016-02-24",78,[792],"Urothelial Carcinoma of the Bladder",[794,795,796,79,797,798],"Methotrexate","Vinblastine","Doxorubicin","5-FU","Mitomycin C",{"nctId":800,"briefTitle":801,"status":130,"phases":802,"primaryCompletion":803,"completion":804,"start":805,"enrollment":109,"conditions":806,"interventions":807},"NCT00003264","Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer",[88],"2002-02","2002-06","1997-10",[304],[708,370],{"nctId":76,"briefTitle":77,"status":104,"phases":809,"primaryCompletion":78,"completion":810,"start":811,"enrollment":109,"conditions":812,"interventions":814},[88],"2027-09-23","2023-03-14",[813],"Oropharynx Cancer",[79],{"nctId":699,"briefTitle":700,"status":130,"phases":816,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":817,"interventions":818},[88],[304,14],[358,708,359],{"nctId":820,"briefTitle":821,"status":142,"phases":822,"primaryCompletion":823,"completion":824,"start":825,"enrollment":826,"conditions":827,"interventions":834},"NCT01611662","Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer",[88],"2013-07-12","2019-01-22","2012-05-29",32,[828,829,830,831,832,833],"Distal Urethral Cancer","Proximal Urethral Cancer","Squamous Cell Carcinoma of the Bladder","Stage II Bladder Cancer","Stage III Bladder Cancer","Urethral Cancer Associated With Invasive Bladder Cancer",[370,708],{"nctId":728,"briefTitle":729,"status":130,"phases":836,"primaryCompletion":731,"completion":732,"start":733,"enrollment":135,"conditions":837,"interventions":838},[88],[423],[708,736,359],{"trials":840,"activeCount":98},[],{"trials":842,"activeCount":98},[],{"trials":844,"activeCount":98},[],{"intervention":397,"totalTrials":9,"cells":846},{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":904,"PHASE3":926,"PHASE4":928,"NA":930},{"trials":848,"activeCount":98},[],{"trials":850,"activeCount":98},[851,855,894],{"nctId":387,"briefTitle":388,"status":130,"phases":852,"primaryCompletion":390,"completion":390,"start":391,"enrollment":135,"conditions":853,"interventions":854},[87],[393,394,395],[397,343,398],{"nctId":856,"briefTitle":857,"status":130,"phases":858,"primaryCompletion":859,"completion":859,"start":860,"enrollment":21,"conditions":861,"interventions":893},"NCT01637194","Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer",[87],"2011-07","2008-11",[862,863,864,865,866,867,868,436,869,870,437,438,439,440,441,442,443,444,445,871,872,873,874,875,448,449,450,451,452,454,455,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,456],"Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Colon Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVA Colon Cancer","Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Colon Cancer","Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",[397,459],{"nctId":895,"briefTitle":896,"status":181,"phases":897,"primaryCompletion":898,"completion":898,"start":899,"enrollment":98,"conditions":900,"interventions":901},"NCT01332279","Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy",[87],"2011-05","2011-04",[436,437,438,439,440,442,443,444,445,446,456],[397,460,902,903],"polyacrylamide gel electrophoresis","microarray analysis",{"trials":905,"activeCount":114,"soonestReadout":242},[906,916],{"nctId":907,"briefTitle":908,"status":142,"phases":909,"primaryCompletion":910,"completion":910,"start":911,"enrollment":604,"conditions":912,"interventions":914},"NCT02539459","Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus",[88],"2018-08-20","2015-09-23",[913],"Sporadic Angiomyolipomas (AMLs)",[915],"Everolimus",{"nctId":917,"briefTitle":918,"status":118,"phases":919,"primaryCompletion":242,"completion":242,"start":920,"enrollment":921,"conditions":922,"interventions":924},"NCT03114527","Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)",[88],"2017-08-08",48,[923],"Soft Tissue Sarcoma",[925,915],"Ribociclib",{"trials":927,"activeCount":98},[],{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"intervention":933,"totalTrials":147,"cells":934},"rituximab",{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[],{"trials":940,"activeCount":114,"soonestReadout":956},[941,951,964],{"nctId":942,"briefTitle":943,"status":130,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":9,"conditions":947,"interventions":949},"NCT00062296","Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",[88],"2005-08","2003-03",[948,28],"Leukemia",[933,950],"epirubicin hydrochloride",{"nctId":952,"briefTitle":953,"status":954,"phases":955,"primaryCompletion":956,"completion":957,"start":958,"enrollment":433,"conditions":959,"interventions":961},"NCT06557330","MRD Guided De-intensification of Bendamustine\u002FRituximab for Indolent Non-Hodgkin Lymphoma","NOT_YET_RECRUITING",[88],"2027-09-29","2028-03-30","2025-06",[28,960],"Indolent Non-hodgkin Lymphoma",[962,963],"Bendamustine","Rituximab",{"nctId":965,"briefTitle":966,"status":181,"phases":967,"enrollment":98,"conditions":968,"interventions":974},"NCT01539174","Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma",[88],[969,970,971,972,973],"Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma",[933,499,975,976,977],"doxorubicin hydrochloride","vincristine sulfate","prednisone",{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[],{"intervention":985,"totalTrials":147,"cells":986},"docetaxel",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":98},[],{"trials":992,"activeCount":114,"soonestReadout":311},[993,997,1007],{"nctId":308,"briefTitle":309,"status":104,"phases":994,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":995,"interventions":996},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"nctId":998,"briefTitle":999,"status":130,"phases":1000,"primaryCompletion":1001,"completion":1002,"start":1003,"enrollment":26,"conditions":1004,"interventions":1005},"NCT00039520","Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer",[88],"2004-06","2008-07","2002-01",[17],[985,1006],"sulindac",{"nctId":1008,"briefTitle":1009,"status":142,"phases":1010,"primaryCompletion":860,"completion":732,"start":1011,"enrollment":826,"conditions":1012,"interventions":1013},"NCT00066677","Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer",[88],"2003-10",[31],[1014,985],"rhuMAB-VEGF",{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"intervention":566,"totalTrials":548,"cells":1022},{"EARLY_PHASE1":1023,"PHASE1":1025,"PHASE2":1038,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1024,"activeCount":98},[],{"trials":1026,"activeCount":98},[1027],{"nctId":1028,"briefTitle":1029,"status":130,"phases":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1035},"NCT00084513","Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2\u002FNeu-Expressing Cancer",[87],"2007-03","2004-08",18,[25],[1036,1037],"trastuzumab","imatinib mesylate",{"trials":1039,"activeCount":114,"soonestReadout":242},[1040],{"nctId":557,"briefTitle":558,"status":118,"phases":1041,"primaryCompletion":242,"completion":560,"start":561,"enrollment":562,"conditions":1042,"interventions":1043},[88],[564],[40,319,566,567],{"trials":1045,"activeCount":98},[],{"trials":1047,"activeCount":98},[],{"trials":1049,"activeCount":98},[],{"intervention":306,"totalTrials":548,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[],{"trials":1057,"activeCount":114,"soonestReadout":311},[1058,1062],{"nctId":296,"briefTitle":297,"status":142,"phases":1059,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":1060,"interventions":1061},[88],[304],[306,287],{"nctId":308,"briefTitle":309,"status":104,"phases":1063,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":1064,"interventions":1065},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"trials":1067,"activeCount":98},[],{"trials":1069,"activeCount":98},[],{"trials":1071,"activeCount":98},[],{"intervention":671,"totalTrials":548,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1088,"PHASE4":1090,"NA":1092},{"trials":1075,"activeCount":98},[],{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":114,"soonestReadout":311},[1080,1084],{"nctId":661,"briefTitle":662,"status":130,"phases":1081,"primaryCompletion":664,"completion":665,"start":666,"enrollment":147,"conditions":1082,"interventions":1083},[88],[28],[358,669,499,670,671,672,673,359],{"nctId":308,"briefTitle":309,"status":104,"phases":1085,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":1086,"interventions":1087},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"trials":1089,"activeCount":98},[],{"trials":1091,"activeCount":98},[],{"trials":1093,"activeCount":98},[],{"intervention":925,"totalTrials":548,"cells":1095},{"EARLY_PHASE1":1096,"PHASE1":1108,"PHASE2":1110,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1097,"activeCount":98},[1098],{"nctId":1099,"briefTitle":1100,"status":142,"phases":1101,"primaryCompletion":1102,"completion":1103,"start":1104,"enrollment":114,"conditions":1105,"interventions":1107},"NCT03179956","Impact of Ribociclib on Head and Neck Squamous Cell Cancer",[86],"2018-11-12","2019-01-10","2018-04-02",[1106],"Squamous Cell Carcinoma of the Head and Neck",[925],{"trials":1109,"activeCount":98},[],{"trials":1111,"activeCount":114,"soonestReadout":242},[1112],{"nctId":917,"briefTitle":918,"status":118,"phases":1113,"primaryCompletion":242,"completion":242,"start":920,"enrollment":921,"conditions":1114,"interventions":1115},[88],[923],[925,915],{"trials":1117,"activeCount":98},[],{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"intervention":1123,"totalTrials":114,"cells":1124},"Venofer",{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1142,"PHASE4":1144,"NA":1146},{"trials":1126,"activeCount":98},[],{"trials":1128,"activeCount":98},[],{"trials":1130,"activeCount":114,"soonestReadout":1135},[1131],{"nctId":1132,"briefTitle":1133,"status":104,"phases":1134,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1141},"NCT05800600","Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy",[88],"2027-02-01","2028-02-01","2023-03-15",34,[1140],"Anemia",[1123],{"trials":1143,"activeCount":98},[],{"trials":1145,"activeCount":98},[],{"trials":1147,"activeCount":98},[],{"intervention":567,"totalTrials":114,"cells":1149},{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1160,"PHASE4":1162,"NA":1164},{"trials":1151,"activeCount":98},[],{"trials":1153,"activeCount":98},[],{"trials":1155,"activeCount":114,"soonestReadout":242},[1156],{"nctId":557,"briefTitle":558,"status":118,"phases":1157,"primaryCompletion":242,"completion":560,"start":561,"enrollment":562,"conditions":1158,"interventions":1159},[88],[564],[40,319,566,567],{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[],{"trials":1165,"activeCount":98},[],{"intervention":59,"totalTrials":114,"cells":1167},{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1182,"PHASE4":1184,"NA":1186},{"trials":1169,"activeCount":98},[],{"trials":1171,"activeCount":98},[],{"trials":1173,"activeCount":114,"soonestReadout":54},[1174],{"nctId":57,"briefTitle":58,"status":118,"phases":1175,"primaryCompletion":54,"completion":1176,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1181},[88],"2028-11","2020-12-01",81,[1180],"Muscle-Invasive Bladder Carcinoma",[59],{"trials":1183,"activeCount":98},[],{"trials":1185,"activeCount":98},[],{"trials":1187,"activeCount":98},[],{"intervention":45,"totalTrials":114,"cells":1189},{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1191,"activeCount":98},[],{"trials":1193,"activeCount":98},[],{"trials":1195,"activeCount":114,"soonestReadout":44},[1196],{"nctId":42,"briefTitle":43,"status":118,"phases":1197,"primaryCompletion":44,"completion":1198,"start":1199,"enrollment":486,"conditions":1200,"interventions":1202},[88],"2027-03-01","2018-05-11",[1201],"Rectal Cancer",[45],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"intervention":226,"totalTrials":114,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":98},[],{"trials":1216,"activeCount":114,"soonestReadout":219},[1217],{"nctId":216,"briefTitle":217,"status":118,"phases":1218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":1219,"interventions":1220},[87,88],[224],[195,226],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"intervention":1228,"totalTrials":114,"cells":1229},"Arm A",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":98},[],{"trials":1235,"activeCount":114,"soonestReadout":242},[1236],{"nctId":1237,"briefTitle":1238,"status":118,"phases":1239,"primaryCompletion":242,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1245},"NCT03786692","Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+\u002F- Atezolizumab in Stage IV NSCLC",[88],"2028-01","2019-09-04",107,[1244],"Non-Small Cell Carcinoma of Lung, TNM Stage 4",[1228,1246],"Arm B",{"trials":1248,"activeCount":98},[],{"trials":1250,"activeCount":98},[],{"trials":1252,"activeCount":98},[],{"intervention":1246,"totalTrials":114,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":98},[],{"trials":1258,"activeCount":98},[],{"trials":1260,"activeCount":114,"soonestReadout":242},[1261],{"nctId":1237,"briefTitle":1238,"status":118,"phases":1262,"primaryCompletion":242,"completion":1240,"start":1241,"enrollment":1242,"conditions":1263,"interventions":1264},[88],[1244],[1228,1246],{"trials":1266,"activeCount":98},[],{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"intervention":320,"totalTrials":114,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1274,"activeCount":98},[],{"trials":1276,"activeCount":98},[],{"trials":1278,"activeCount":114,"soonestReadout":311},[1279],{"nctId":308,"briefTitle":309,"status":104,"phases":1280,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":1281,"interventions":1282},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"trials":1284,"activeCount":98},[],{"trials":1286,"activeCount":98},[],{"trials":1288,"activeCount":98},[],{"intervention":323,"totalTrials":114,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1301,"PHASE4":1303,"NA":1305},{"trials":1292,"activeCount":98},[],{"trials":1294,"activeCount":98},[],{"trials":1296,"activeCount":114,"soonestReadout":311},[1297],{"nctId":308,"briefTitle":309,"status":104,"phases":1298,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":1299,"interventions":1300},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":98},[],{"intervention":324,"totalTrials":114,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":114,"soonestReadout":311},[1315],{"nctId":308,"briefTitle":309,"status":104,"phases":1316,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":1317,"interventions":1318},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":98},[],{"intervention":325,"totalTrials":114,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":114,"soonestReadout":311},[1333],{"nctId":308,"briefTitle":309,"status":104,"phases":1334,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":1335,"interventions":1336},[88],[14,316,260],[125,318,319,320,321,126,322,323,324,325],{"trials":1338,"activeCount":98},[],{"trials":1340,"activeCount":98},[],{"trials":1342,"activeCount":98},[],{"intervention":962,"totalTrials":114,"cells":1344},{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1346,"activeCount":98},[],{"trials":1348,"activeCount":98},[],{"trials":1350,"activeCount":114,"soonestReadout":956},[1351],{"nctId":952,"briefTitle":953,"status":954,"phases":1352,"primaryCompletion":956,"completion":957,"start":958,"enrollment":433,"conditions":1353,"interventions":1354},[88],[28,960],[962,963],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"intervention":74,"totalTrials":114,"cells":1362},{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1375,"PHASE4":1377,"NA":1379},{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"trials":1368,"activeCount":114,"soonestReadout":73},[1369],{"nctId":71,"briefTitle":72,"status":118,"phases":1370,"primaryCompletion":73,"completion":73,"start":1371,"enrollment":1372,"conditions":1373,"interventions":1374},[88],"2022-04-22",37,[285],[74],{"trials":1376,"activeCount":98},[],{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":98},[],{"intervention":251,"totalTrials":114,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[],{"trials":1388,"activeCount":114,"soonestReadout":242},[1389],{"nctId":239,"briefTitle":240,"status":104,"phases":1390,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":1391,"interventions":1392},[88],[247,248,137,249],[251,195],{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[],{"intervention":262,"totalTrials":114,"cells":1400},{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1402,"activeCount":98},[],{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":114,"soonestReadout":242},[1407],{"nctId":253,"briefTitle":254,"status":118,"phases":1408,"primaryCompletion":242,"completion":256,"start":257,"enrollment":258,"conditions":1409,"interventions":1410},[88],[260],[195,262],{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"intervention":574,"totalTrials":114,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1420,"activeCount":98},[],{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":114,"soonestReadout":39},[1425],{"nctId":37,"briefTitle":38,"status":118,"phases":1426,"primaryCompletion":39,"completion":570,"start":571,"enrollment":135,"conditions":1427,"interventions":1428},[88],[34],[40,574],{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[],{"intervention":113,"totalTrials":114,"cells":1436},{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1445,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1438,"activeCount":98},[],{"trials":1440,"activeCount":114,"soonestReadout":106},[1441],{"nctId":102,"briefTitle":103,"status":104,"phases":1442,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":1443,"interventions":1444},[87],[111],[113,55],{"trials":1446,"activeCount":98},[],{"trials":1448,"activeCount":98},[],{"trials":1450,"activeCount":98},[],{"trials":1452,"activeCount":98},[],{"intervention":1454,"totalTrials":114,"cells":1455},"Talazoparib",{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1475,"PHASE3":1477,"PHASE4":1479,"NA":1481},{"trials":1457,"activeCount":98},[],{"trials":1459,"activeCount":114,"soonestReadout":1464},[1460],{"nctId":1461,"briefTitle":1462,"status":104,"phases":1463,"primaryCompletion":1464,"completion":1465,"start":1466,"enrollment":433,"conditions":1467,"interventions":1473},"NCT06218628","Pacritinib w\u002F Talazoparib in Pts w\u002F Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition",[87],"2029-08-22","2030-08-27","2024-04-05",[1468,1469,1470,472,1471,1472],"Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Polycythemia Vera","Essential Thrombocytosis",[1454,1474],"pacritinib",{"trials":1476,"activeCount":98},[],{"trials":1478,"activeCount":98},[],{"trials":1480,"activeCount":98},[],{"trials":1482,"activeCount":98},[],{"intervention":1474,"totalTrials":114,"cells":1484},{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":114,"soonestReadout":1464},[1489],{"nctId":1461,"briefTitle":1462,"status":104,"phases":1490,"primaryCompletion":1464,"completion":1465,"start":1466,"enrollment":433,"conditions":1491,"interventions":1492},[87],[1468,1469,1470,472,1471,1472],[1454,1474],{"trials":1494,"activeCount":98},[],{"trials":1496,"activeCount":98},[],{"trials":1498,"activeCount":98},[],{"trials":1500,"activeCount":98},[],{"intervention":64,"totalTrials":114,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":114,"soonestReadout":63},[1507],{"nctId":61,"briefTitle":62,"status":104,"phases":1508,"primaryCompletion":63,"completion":1509,"start":1510,"enrollment":1033,"conditions":1511,"interventions":1515},[87],"2027-06","2022-06-24",[1512,1513,1514],"Gastric Cancer","Gastrointestinal Cancer","HER2 Gene Mutation",[64,1516],"Fam-Trastuzumab Deruxtecan-Nxki",{"trials":1518,"activeCount":98},[],{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":98},[],{"intervention":1516,"totalTrials":114,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":98},[],{"trials":1530,"activeCount":114,"soonestReadout":63},[1531],{"nctId":61,"briefTitle":62,"status":104,"phases":1532,"primaryCompletion":63,"completion":1509,"start":1510,"enrollment":1033,"conditions":1533,"interventions":1534},[87],[1512,1513,1514],[64,1516],{"trials":1536,"activeCount":98},[],{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"intervention":69,"totalTrials":114,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1557,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1546,"activeCount":98},[],{"trials":1548,"activeCount":114,"soonestReadout":68},[1549],{"nctId":66,"briefTitle":67,"status":104,"phases":1550,"primaryCompletion":68,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1556},[87],"2026-12-30","2021-11-05",42,[28,1555],"Advanced Solid Tumor",[69],{"trials":1558,"activeCount":98},[],{"trials":1560,"activeCount":98},[],{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"intervention":209,"totalTrials":114,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1568,"activeCount":114,"soonestReadout":203},[1569],{"nctId":200,"briefTitle":201,"status":104,"phases":1570,"primaryCompletion":203,"completion":204,"start":205,"enrollment":21,"conditions":1571,"interventions":1572},[86],[207],[209,210,195],{"trials":1574,"activeCount":98},[],{"trials":1576,"activeCount":98},[],{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[],{"trials":1582,"activeCount":98},[],{"intervention":210,"totalTrials":114,"cells":1584},{"EARLY_PHASE1":1585,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1586,"activeCount":114,"soonestReadout":203},[1587],{"nctId":200,"briefTitle":201,"status":104,"phases":1588,"primaryCompletion":203,"completion":204,"start":205,"enrollment":21,"conditions":1589,"interventions":1590},[86],[207],[209,210,195],{"trials":1592,"activeCount":98},[],{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[],{"trials":1600,"activeCount":98},[],{"intervention":50,"totalTrials":114,"cells":1602},{"EARLY_PHASE1":1603,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1620},{"trials":1604,"activeCount":114,"soonestReadout":49},[1605],{"nctId":47,"briefTitle":48,"status":118,"phases":1606,"primaryCompletion":49,"completion":1607,"start":1608,"enrollment":604,"conditions":1609,"interventions":1611},[86],"2026-12-31","2021-10-20",[1610],"Pancreatic Ductal Adenocarcinoma",[50],{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"trials":1619,"activeCount":98},[],{"trials":1621,"activeCount":98},[],{"intervention":1623,"totalTrials":114,"cells":1624},"Cannabidiol",{"EARLY_PHASE1":1625,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1626,"activeCount":114,"soonestReadout":1631},[1627],{"nctId":1628,"briefTitle":1629,"status":104,"phases":1630,"primaryCompletion":1631,"completion":1632,"start":1633,"enrollment":1634,"conditions":1635,"interventions":1639},"NCT07167446","Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy",[86],"2027-09-05","2028-09-07","2025-10-14",30,[1636,1637,1638],"Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","Metastatic Colorectal Cancer (CRC)","Peripheral Neuropathy Due to Chemotherapy",[1623,1640],"oxaliplatin-based chemotherapy",{"trials":1642,"activeCount":98},[],{"trials":1644,"activeCount":98},[],{"trials":1646,"activeCount":98},[],{"trials":1648,"activeCount":98},[],{"trials":1650,"activeCount":98},[],{"intervention":1640,"totalTrials":114,"cells":1652},{"EARLY_PHASE1":1653,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1654,"activeCount":114,"soonestReadout":1631},[1655],{"nctId":1628,"briefTitle":1629,"status":104,"phases":1656,"primaryCompletion":1631,"completion":1632,"start":1633,"enrollment":1634,"conditions":1657,"interventions":1658},[86],[1636,1637,1638],[1623,1640],{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[],{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[],{"intervention":796,"totalTrials":548,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1672,"activeCount":98},[],{"trials":1674,"activeCount":98},[],{"trials":1676,"activeCount":98},[1677],{"nctId":784,"briefTitle":785,"status":130,"phases":1678,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":1679,"interventions":1680},[88],[792],[794,795,796,79,797,798],{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":114,"soonestReadout":83},[1687],{"nctId":81,"briefTitle":82,"status":118,"phases":1688,"primaryCompletion":83,"completion":1689,"start":1690,"enrollment":433,"conditions":1691,"interventions":1692},[],"2027-10","2016-08-12",[923],[84,796],{"intervention":1694,"totalTrials":114,"cells":1695},"Immune checkpoint inhibitor targeting PD1",{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1702,"PHASE4":1704,"NA":1706},{"trials":1697,"activeCount":98},[],{"trials":1699,"activeCount":98},[],{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":114,"soonestReadout":242},[1708],{"nctId":1709,"briefTitle":1710,"status":118,"phases":1711,"primaryCompletion":242,"completion":242,"start":571,"enrollment":15,"conditions":1712,"interventions":1716},"NCT03291028","Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma",[],[224,34,1713,1714,1715],"Bladder Cancer","Ureter Cancer","Urethral Cancer",[1694],{"intervention":84,"totalTrials":114,"cells":1718},{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1725,"PHASE4":1727,"NA":1729},{"trials":1720,"activeCount":98},[],{"trials":1722,"activeCount":98},[],{"trials":1724,"activeCount":98},[],{"trials":1726,"activeCount":98},[],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":114,"soonestReadout":83},[1731],{"nctId":81,"briefTitle":82,"status":118,"phases":1732,"primaryCompletion":83,"completion":1689,"start":1690,"enrollment":433,"conditions":1733,"interventions":1734},[],[923],[84,796],{"intervention":1736,"totalTrials":114,"cells":1737},"Use of buprenorphine with FAO > 30 OME",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1744,"PHASE4":1746,"NA":1758},{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[],{"trials":1745,"activeCount":98},[],{"trials":1747,"activeCount":98},[1748],{"nctId":1749,"briefTitle":1750,"status":416,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":1754,"conditions":1755,"interventions":1757},"NCT05910190","Buprenorphine for Cancer Pain",[90],"2024-10-10","2022-08-10",50,[1756],"Cancer-Related Pain",[1736],{"trials":1759,"activeCount":98},[],{"intervention":1761,"totalTrials":114,"cells":1762},"nicotine lozenge",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1769,"PHASE4":1771,"NA":1787},{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[],{"trials":1772,"activeCount":98},[1773],{"nctId":1774,"briefTitle":1775,"status":130,"phases":1776,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1779,"conditions":1780,"interventions":1785},"NCT00365508","Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking",[90],"2009-08","2006-02",642,[1713,1781,423,1512,304,1782,948,1783,14,31,1784],"Cervical Cancer","Kidney Cancer","Liver Cancer","Tobacco Use Disorder",[1761,1786],"nicotine patch",{"trials":1788,"activeCount":98},[],{"intervention":1786,"totalTrials":114,"cells":1790},{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1797,"PHASE4":1799,"NA":1805},{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"trials":1796,"activeCount":98},[],{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[1801],{"nctId":1774,"briefTitle":1775,"status":130,"phases":1802,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1779,"conditions":1803,"interventions":1804},[90],[1713,1781,423,1512,304,1782,948,1783,14,31,1784],[1761,1786],{"trials":1806,"activeCount":98},[],{"intervention":370,"totalTrials":9,"cells":1808},{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1829,"PHASE3":1839,"PHASE4":1845,"NA":1847},{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[1813,1817],{"nctId":362,"briefTitle":363,"status":130,"phases":1814,"primaryCompletion":365,"completion":366,"start":367,"enrollment":29,"conditions":1815,"interventions":1816},[87],[25],[343,370],{"nctId":1818,"briefTitle":1819,"status":142,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":32,"conditions":1823,"interventions":1828},"NCT01739439","Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery",[87],"2015-12-01","2013-05",[1824,1825,1826,1827],"Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Stage IIB Pancreatic Cancer","Stage III Pancreatic Cancer",[370],{"trials":1830,"activeCount":98},[1831,1835],{"nctId":800,"briefTitle":801,"status":130,"phases":1832,"primaryCompletion":803,"completion":804,"start":805,"enrollment":109,"conditions":1833,"interventions":1834},[88],[304],[708,370],{"nctId":820,"briefTitle":821,"status":142,"phases":1836,"primaryCompletion":823,"completion":824,"start":825,"enrollment":826,"conditions":1837,"interventions":1838},[88],[828,829,830,831,832,833],[370,708],{"trials":1840,"activeCount":98},[1841],{"nctId":529,"briefTitle":530,"status":181,"phases":1842,"primaryCompletion":532,"completion":532,"start":532,"enrollment":98,"conditions":1843,"interventions":1844},[89],[14],[343,370,359],{"trials":1846,"activeCount":98},[],{"trials":1848,"activeCount":98},[],{"intervention":358,"totalTrials":9,"cells":1850},{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1859,"PHASE3":1877,"PHASE4":1879,"NA":1881},{"trials":1852,"activeCount":98},[],{"trials":1854,"activeCount":98},[1855],{"nctId":350,"briefTitle":351,"status":130,"phases":1856,"primaryCompletion":353,"completion":353,"start":354,"enrollment":302,"conditions":1857,"interventions":1858},[87],[28,356,25],[358,343,359,360],{"trials":1860,"activeCount":98},[1861,1865,1869,1873],{"nctId":490,"briefTitle":491,"status":130,"phases":1862,"primaryCompletion":493,"completion":494,"start":495,"enrollment":147,"conditions":1863,"interventions":1864},[88],[393,497,394],[358,343,499,359,360],{"nctId":501,"briefTitle":502,"status":130,"phases":1866,"primaryCompletion":504,"completion":494,"start":505,"enrollment":147,"conditions":1867,"interventions":1868},[88],[507,14],[358,343,499,359,360],{"nctId":661,"briefTitle":662,"status":130,"phases":1870,"primaryCompletion":664,"completion":665,"start":666,"enrollment":147,"conditions":1871,"interventions":1872},[88],[28],[358,669,499,670,671,672,673,359],{"nctId":699,"briefTitle":700,"status":130,"phases":1874,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":1875,"interventions":1876},[88],[304,14],[358,708,359],{"trials":1878,"activeCount":98},[],{"trials":1880,"activeCount":98},[],{"trials":1882,"activeCount":98},[],{"intervention":360,"totalTrials":1884,"cells":1885},4,{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1894,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1887,"activeCount":98},[],{"trials":1889,"activeCount":98},[1890],{"nctId":350,"briefTitle":351,"status":130,"phases":1891,"primaryCompletion":353,"completion":353,"start":354,"enrollment":302,"conditions":1892,"interventions":1893},[87],[28,356,25],[358,343,359,360],{"trials":1895,"activeCount":98},[1896,1900,1904],{"nctId":490,"briefTitle":491,"status":130,"phases":1897,"primaryCompletion":493,"completion":494,"start":495,"enrollment":147,"conditions":1898,"interventions":1899},[88],[393,497,394],[358,343,499,359,360],{"nctId":501,"briefTitle":502,"status":130,"phases":1901,"primaryCompletion":504,"completion":494,"start":505,"enrollment":147,"conditions":1902,"interventions":1903},[88],[507,14],[358,343,499,359,360],{"nctId":720,"briefTitle":721,"status":181,"phases":1905,"primaryCompletion":723,"completion":723,"start":724,"enrollment":98,"conditions":1906,"interventions":1907},[88],[23],[718,359,360],{"trials":1909,"activeCount":98},[],{"trials":1911,"activeCount":98},[],{"trials":1913,"activeCount":98},[],{"intervention":499,"totalTrials":1884,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1917,"activeCount":98},[],{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[1922,1926,1930,1934],{"nctId":490,"briefTitle":491,"status":130,"phases":1923,"primaryCompletion":493,"completion":494,"start":495,"enrollment":147,"conditions":1924,"interventions":1925},[88],[393,497,394],[358,343,499,359,360],{"nctId":501,"briefTitle":502,"status":130,"phases":1927,"primaryCompletion":504,"completion":494,"start":505,"enrollment":147,"conditions":1928,"interventions":1929},[88],[507,14],[358,343,499,359,360],{"nctId":661,"briefTitle":662,"status":130,"phases":1931,"primaryCompletion":664,"completion":665,"start":666,"enrollment":147,"conditions":1932,"interventions":1933},[88],[28],[358,669,499,670,671,672,673,359],{"nctId":965,"briefTitle":966,"status":181,"phases":1935,"enrollment":98,"conditions":1936,"interventions":1937},[88],[969,970,971,972,973],[933,499,975,976,977],{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[],{"trials":1943,"activeCount":98},[],{"intervention":525,"totalTrials":147,"cells":1945},{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1950,"PHASE3":1973,"PHASE4":1975,"NA":1977},{"trials":1947,"activeCount":98},[],{"trials":1949,"activeCount":98},[],{"trials":1951,"activeCount":98},[1952,1958,1969],{"nctId":1953,"briefTitle":1954,"status":130,"phases":1955,"primaryCompletion":731,"completion":731,"start":1003,"enrollment":94,"conditions":1956,"interventions":1957},"NCT00022711","Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer",[88],[14],[525],{"nctId":1959,"briefTitle":1960,"status":130,"phases":1961,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1967},"NCT00005037","Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer",[88],"2002-10","2008-04","2000-01",51,[14],[525,1968],"Temozolomide",{"nctId":518,"briefTitle":519,"status":181,"phases":1970,"primaryCompletion":521,"completion":521,"enrollment":98,"conditions":1971,"interventions":1972},[87,88],[523],[343,525],{"trials":1974,"activeCount":98},[],{"trials":1976,"activeCount":98},[],{"trials":1978,"activeCount":98},[],{"intervention":460,"totalTrials":548,"cells":1980},{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1989,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1982,"activeCount":98},[],{"trials":1984,"activeCount":98},[1985],{"nctId":895,"briefTitle":896,"status":181,"phases":1986,"primaryCompletion":898,"completion":898,"start":899,"enrollment":98,"conditions":1987,"interventions":1988},[87],[436,437,438,439,440,442,443,444,445,446,456],[397,460,902,903],{"trials":1990,"activeCount":98},[1991],{"nctId":428,"briefTitle":429,"status":130,"phases":1992,"primaryCompletion":431,"completion":144,"start":432,"enrollment":433,"conditions":1993,"interventions":1994},[88],[435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457],[459,359,343,460],{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"trials":2000,"activeCount":98},[],{"intervention":474,"totalTrials":548,"cells":2002},{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2004,"activeCount":98},[],{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[2009,2013],{"nctId":462,"briefTitle":463,"status":130,"phases":2010,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":2011,"interventions":2012},[88],[470,471,472],[474,125,475],{"nctId":2014,"briefTitle":2015,"status":142,"phases":2016,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":114,"conditions":2020,"interventions":2022},"NCT03113071","Safety and Activity of Digoxin With Decitabine in Adult AML and MDS",[87,88],"2019-01-08","2019-03-11","2017-06-02",[470,2021],"Myelodysplastic Syndromes",[474,2023],"Digoxin",{"trials":2025,"activeCount":98},[],{"trials":2027,"activeCount":98},[],{"trials":2029,"activeCount":98},[],{"intervention":797,"totalTrials":548,"cells":2031},{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2052,"PHASE4":2054,"NA":2056},{"trials":2033,"activeCount":98},[],{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":98},[2038,2042],{"nctId":784,"briefTitle":785,"status":130,"phases":2039,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":2040,"interventions":2041},[88],[792],[794,795,796,79,797,798],{"nctId":2043,"briefTitle":2044,"status":142,"phases":2045,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":548,"conditions":2048,"interventions":2049},"NCT03099486","Regorafenib Plus 5-Fluorouracil\u002FLeucovorin Beyond Progression in mCRC",[88],"2020-06-02","2017-10-06",[20],[2050,797,2051],"Regorafenib","Leucovorin",{"trials":2053,"activeCount":98},[],{"trials":2055,"activeCount":98},[],{"trials":2057,"activeCount":98},[],{"intervention":798,"totalTrials":548,"cells":2059},{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2064,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2061,"activeCount":98},[],{"trials":2063,"activeCount":98},[],{"trials":2065,"activeCount":98},[2066,2070],{"nctId":784,"briefTitle":785,"status":130,"phases":2067,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":2068,"interventions":2069},[88],[792],[794,795,796,79,797,798],{"nctId":2071,"briefTitle":2072,"status":181,"phases":2073,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":98,"conditions":2077,"interventions":2080},"NCT04037072","Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures",[88],"2022-03-15","2022-12-15","2020-04-03",[2078,2079],"Esophageal Stenosis","Anastomotic Stenosis",[798],{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"intervention":2088,"totalTrials":548,"cells":2089},"Nilotinib",{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2091,"activeCount":98},[],{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[2096,2104],{"nctId":2097,"briefTitle":2098,"status":142,"phases":2099,"primaryCompletion":1002,"completion":761,"start":1002,"enrollment":2100,"conditions":2101,"interventions":2103},"NCT00782834","Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)",[88],13,[2102],"Gastrointestinal Stromal Tumors",[2088],{"nctId":2105,"briefTitle":2106,"status":142,"phases":2107,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":9,"conditions":2111,"interventions":2114},"NCT01089595","Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)",[88],"2011-11","2012-03","2009-02",[2112,2113],"GIST","Metastatic Disease",[2088,2115],"Nilotinib with Imatinib",{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"intervention":288,"totalTrials":548,"cells":2123},{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2132,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[2128],{"nctId":276,"briefTitle":277,"status":130,"phases":2129,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":2130,"interventions":2131},[87],[284,285],[287,288],{"trials":2133,"activeCount":98},[2134],{"nctId":2135,"briefTitle":2136,"status":130,"phases":2137,"primaryCompletion":2138,"completion":2139,"start":2140,"enrollment":826,"conditions":2141,"interventions":2143},"NCT00553800","Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer",[88],"2011-01-12","2011-06-01","2007-07-05",[2142],"Carcinoma, Non-Small-Cell Lung",[2144,288],"bevacizumab",{"trials":2146,"activeCount":98},[],{"trials":2148,"activeCount":98},[],{"trials":2150,"activeCount":98},[],{"intervention":718,"totalTrials":548,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[2159,2163],{"nctId":710,"briefTitle":711,"status":130,"phases":2160,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":2161,"interventions":2162},[88],[28],[718,359],{"nctId":720,"briefTitle":721,"status":181,"phases":2164,"primaryCompletion":723,"completion":723,"start":724,"enrollment":98,"conditions":2165,"interventions":2166},[88],[23],[718,359,360],{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[],{"intervention":475,"totalTrials":114,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":98},[],{"trials":2178,"activeCount":98},[],{"trials":2180,"activeCount":98},[2181],{"nctId":462,"briefTitle":463,"status":130,"phases":2182,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":2183,"interventions":2184},[88],[470,471,472],[474,125,475],{"trials":2186,"activeCount":98},[],{"trials":2188,"activeCount":98},[],{"trials":2190,"activeCount":98},[],{"intervention":794,"totalTrials":114,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2194,"activeCount":98},[],{"trials":2196,"activeCount":98},[],{"trials":2198,"activeCount":98},[2199],{"nctId":784,"briefTitle":785,"status":130,"phases":2200,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":2201,"interventions":2202},[88],[792],[794,795,796,79,797,798],{"trials":2204,"activeCount":98},[],{"trials":2206,"activeCount":98},[],{"trials":2208,"activeCount":98},[],{"intervention":795,"totalTrials":114,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[2217],{"nctId":784,"briefTitle":785,"status":130,"phases":2218,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":2219,"interventions":2220},[88],[792],[794,795,796,79,797,798],{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"intervention":2228,"totalTrials":114,"cells":2229},"dexamethasone",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2234,"PHASE3":2247,"PHASE4":2249,"NA":2251},{"trials":2231,"activeCount":98},[],{"trials":2233,"activeCount":98},[],{"trials":2235,"activeCount":98},[2236],{"nctId":2237,"briefTitle":2238,"status":130,"phases":2239,"primaryCompletion":2240,"completion":2241,"start":2242,"enrollment":302,"conditions":2243,"interventions":2245},"NCT00021359","Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma",[88],"2000-07","2005-10","1999-08",[2244],"Multiple Myeloma and Plasma Cell Neoplasm",[2228,2246],"isotretinoin",{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"intervention":2246,"totalTrials":114,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2265,"PHASE4":2267,"NA":2269},{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[2261],{"nctId":2237,"briefTitle":2238,"status":130,"phases":2262,"primaryCompletion":2240,"completion":2241,"start":2242,"enrollment":302,"conditions":2263,"interventions":2264},[88],[2244],[2228,2246],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":98},[],{"intervention":2272,"totalTrials":114,"cells":2273},"Bexarotene 1% gel",{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[],{"trials":2279,"activeCount":98},[2280],{"nctId":2281,"briefTitle":2282,"status":142,"phases":2283,"primaryCompletion":2284,"completion":1032,"start":2285,"enrollment":29,"conditions":2286,"interventions":2288},"NCT00322296","Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis",[88],"2004-07","2001-04",[2287],"Parapsoriasis",[2272],{"trials":2290,"activeCount":98},[],{"trials":2292,"activeCount":98},[],{"trials":2294,"activeCount":98},[],{"intervention":950,"totalTrials":114,"cells":2296},{"EARLY_PHASE1":2297,"PHASE1":2299,"PHASE2":2301,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2298,"activeCount":98},[],{"trials":2300,"activeCount":98},[],{"trials":2302,"activeCount":98},[2303],{"nctId":942,"briefTitle":943,"status":130,"phases":2304,"primaryCompletion":945,"completion":945,"start":946,"enrollment":9,"conditions":2305,"interventions":2306},[88],[948,28],[933,950],{"trials":2308,"activeCount":98},[],{"trials":2310,"activeCount":98},[],{"trials":2312,"activeCount":98},[],{"intervention":2314,"totalTrials":114,"cells":2315},"Quinacrine and Capecitabine",{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2317,"activeCount":98},[],{"trials":2319,"activeCount":98},[],{"trials":2321,"activeCount":98},[2322],{"nctId":2323,"briefTitle":2324,"status":142,"phases":2325,"primaryCompletion":2326,"completion":2326,"start":2327,"enrollment":486,"conditions":2328,"interventions":2330},"NCT01844076","Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma",[87,88],"2019-08-09","2016-01-14",[2329],"Colorectal Adenocarcinoma",[2314],{"trials":2332,"activeCount":98},[],{"trials":2334,"activeCount":98},[],{"trials":2336,"activeCount":98},[],{"intervention":2338,"totalTrials":114,"cells":2339},"therapeutic allogeneic lymphocytes",{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2357,"PHASE4":2359,"NA":2361},{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":98},[],{"trials":2345,"activeCount":98},[2346],{"nctId":2347,"briefTitle":2348,"status":181,"phases":2349,"primaryCompletion":301,"completion":301,"start":2350,"enrollment":98,"conditions":2351,"interventions":2352},"NCT00025519","Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer",[88],"2001-06",[1782],[2338,2353,2354,2355,2356],"fludarabine phosphate","mycophenolate mofetil","tacrolimus","thalidomide",{"trials":2358,"activeCount":98},[],{"trials":2360,"activeCount":98},[],{"trials":2362,"activeCount":98},[],{"intervention":2353,"totalTrials":114,"cells":2364},{"EARLY_PHASE1":2365,"PHASE1":2367,"PHASE2":2369,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2366,"activeCount":98},[],{"trials":2368,"activeCount":98},[],{"trials":2370,"activeCount":98},[2371],{"nctId":2347,"briefTitle":2348,"status":181,"phases":2372,"primaryCompletion":301,"completion":301,"start":2350,"enrollment":98,"conditions":2373,"interventions":2374},[88],[1782],[2338,2353,2354,2355,2356],{"trials":2376,"activeCount":98},[],{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[],{"intervention":2354,"totalTrials":114,"cells":2382},{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2387,"PHASE3":2393,"PHASE4":2395,"NA":2397},{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[2389],{"nctId":2347,"briefTitle":2348,"status":181,"phases":2390,"primaryCompletion":301,"completion":301,"start":2350,"enrollment":98,"conditions":2391,"interventions":2392},[88],[1782],[2338,2353,2354,2355,2356],{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":98},[],{"trials":2398,"activeCount":98},[],{"intervention":2355,"totalTrials":114,"cells":2400},{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2405,"PHASE3":2411,"PHASE4":2413,"NA":2415},{"trials":2402,"activeCount":98},[],{"trials":2404,"activeCount":98},[],{"trials":2406,"activeCount":98},[2407],{"nctId":2347,"briefTitle":2348,"status":181,"phases":2408,"primaryCompletion":301,"completion":301,"start":2350,"enrollment":98,"conditions":2409,"interventions":2410},[88],[1782],[2338,2353,2354,2355,2356],{"trials":2412,"activeCount":98},[],{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[],{"intervention":2356,"totalTrials":114,"cells":2418},{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2429,"PHASE4":2431,"NA":2433},{"trials":2420,"activeCount":98},[],{"trials":2422,"activeCount":98},[],{"trials":2424,"activeCount":98},[2425],{"nctId":2347,"briefTitle":2348,"status":181,"phases":2426,"primaryCompletion":301,"completion":301,"start":2350,"enrollment":98,"conditions":2427,"interventions":2428},[88],[1782],[2338,2353,2354,2355,2356],{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[],{"trials":2434,"activeCount":98},[],{"intervention":2436,"totalTrials":114,"cells":2437},"semaxanib",{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2442,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[2444],{"nctId":2445,"briefTitle":2446,"status":130,"phases":2447,"primaryCompletion":2448,"completion":2448,"start":2449,"enrollment":135,"conditions":2450,"interventions":2451},"NCT00006013","SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma",[88],"2003-01","2000-06",[2244],[2436],{"trials":2453,"activeCount":98},[],{"trials":2455,"activeCount":98},[],{"trials":2457,"activeCount":98},[],{"intervention":2459,"totalTrials":114,"cells":2460},"ONC201",{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2462,"activeCount":98},[],{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[2467],{"nctId":2468,"briefTitle":2469,"status":142,"phases":2470,"primaryCompletion":2471,"completion":2471,"start":2472,"enrollment":486,"conditions":2473,"interventions":2475},"NCT03099499","Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer",[88],"2020-09-09","2017-06-08",[2474],"Endometrial Cancer",[2459],{"trials":2477,"activeCount":98},[],{"trials":2479,"activeCount":98},[],{"trials":2481,"activeCount":98},[],{"intervention":152,"totalTrials":114,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2494,"PHASE4":2496,"NA":2498},{"trials":2485,"activeCount":98},[],{"trials":2487,"activeCount":98},[],{"trials":2489,"activeCount":98},[2490],{"nctId":140,"briefTitle":141,"status":142,"phases":2491,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":2492,"interventions":2493},[87,88],[149,150],[152,55],{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"trials":2499,"activeCount":98},[],{"intervention":669,"totalTrials":114,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2512,"PHASE4":2514,"NA":2516},{"trials":2503,"activeCount":98},[],{"trials":2505,"activeCount":98},[],{"trials":2507,"activeCount":98},[2508],{"nctId":661,"briefTitle":662,"status":130,"phases":2509,"primaryCompletion":664,"completion":665,"start":666,"enrollment":147,"conditions":2510,"interventions":2511},[88],[28],[358,669,499,670,671,672,673,359],{"trials":2513,"activeCount":98},[],{"trials":2515,"activeCount":98},[],{"trials":2517,"activeCount":98},[],{"intervention":670,"totalTrials":114,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2521,"activeCount":98},[],{"trials":2523,"activeCount":98},[],{"trials":2525,"activeCount":98},[2526],{"nctId":661,"briefTitle":662,"status":130,"phases":2527,"primaryCompletion":664,"completion":665,"start":666,"enrollment":147,"conditions":2528,"interventions":2529},[88],[28],[358,669,499,670,671,672,673,359],{"trials":2531,"activeCount":98},[],{"trials":2533,"activeCount":98},[],{"trials":2535,"activeCount":98},[],{"intervention":672,"totalTrials":114,"cells":2537},{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2548,"PHASE4":2550,"NA":2552},{"trials":2539,"activeCount":98},[],{"trials":2541,"activeCount":98},[],{"trials":2543,"activeCount":98},[2544],{"nctId":661,"briefTitle":662,"status":130,"phases":2545,"primaryCompletion":664,"completion":665,"start":666,"enrollment":147,"conditions":2546,"interventions":2547},[88],[28],[358,669,499,670,671,672,673,359],{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":98},[],{"intervention":673,"totalTrials":114,"cells":2555},{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2560,"PHASE3":2566,"PHASE4":2568,"NA":2570},{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[2562],{"nctId":661,"briefTitle":662,"status":130,"phases":2563,"primaryCompletion":664,"completion":665,"start":666,"enrollment":147,"conditions":2564,"interventions":2565},[88],[28],[358,669,499,670,671,672,673,359],{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[],{"intervention":2573,"totalTrials":114,"cells":2574},"Epacadostat + pembrolizumab",{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2576,"activeCount":98},[],{"trials":2578,"activeCount":98},[],{"trials":2580,"activeCount":98},[2581],{"nctId":2582,"briefTitle":2583,"status":181,"phases":2584,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":98,"conditions":2587,"interventions":2589},"NCT03310567","A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent\u002FMetastatic Endometrial Carcinoma",[88],"2018-09-10","2018-09",[2588],"Recurrent\u002F Metastatic Endometrial Carcinoma",[2573],{"trials":2591,"activeCount":98},[],{"trials":2593,"activeCount":98},[],{"trials":2595,"activeCount":98},[],{"intervention":2597,"totalTrials":114,"cells":2598},"Glucarpidase",{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2603,"PHASE3":2615,"PHASE4":2617,"NA":2619},{"trials":2600,"activeCount":98},[],{"trials":2602,"activeCount":98},[],{"trials":2604,"activeCount":98},[2605],{"nctId":2606,"briefTitle":2607,"status":2608,"phases":2609,"primaryCompletion":2610,"completion":2611,"start":2612,"enrollment":147,"conditions":2613,"interventions":2614},"NCT04668768","HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma","SUSPENDED",[88],"2024-12","2025-04","2021-04-16",[28],[2597],{"trials":2616,"activeCount":98},[],{"trials":2618,"activeCount":98},[],{"trials":2620,"activeCount":98},[],{"intervention":683,"totalTrials":114,"cells":2622},{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2624,"activeCount":98},[],{"trials":2626,"activeCount":98},[],{"trials":2628,"activeCount":98},[2629],{"nctId":675,"briefTitle":676,"status":142,"phases":2630,"primaryCompletion":678,"completion":678,"start":679,"enrollment":604,"conditions":2631,"interventions":2632},[88],[316,681],[683,319],{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[],{"intervention":2640,"totalTrials":114,"cells":2641},"pazopanib hydrochloride",{"EARLY_PHASE1":2642,"PHASE1":2644,"PHASE2":2646,"PHASE3":2661,"PHASE4":2663,"NA":2665},{"trials":2643,"activeCount":98},[],{"trials":2645,"activeCount":98},[],{"trials":2647,"activeCount":98},[2648],{"nctId":2649,"briefTitle":2650,"status":130,"phases":2651,"primaryCompletion":2652,"completion":2653,"start":2654,"enrollment":705,"conditions":2655,"interventions":2660},"NCT01462630","Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma",[88],"2019-01-02","2021-01-12","2011-11-03",[2656,2657,2658,2659],"Adult Angiosarcoma","Recurrent Adult Soft Tissue Sarcoma","Stage III Adult Soft Tissue Sarcoma","Stage IV Adult Soft Tissue Sarcoma",[2640],{"trials":2662,"activeCount":98},[],{"trials":2664,"activeCount":98},[],{"trials":2666,"activeCount":98},[],{"intervention":2050,"totalTrials":114,"cells":2668},{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2679,"PHASE4":2681,"NA":2683},{"trials":2670,"activeCount":98},[],{"trials":2672,"activeCount":98},[],{"trials":2674,"activeCount":98},[2675],{"nctId":2043,"briefTitle":2044,"status":142,"phases":2676,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":548,"conditions":2677,"interventions":2678},[88],[20],[2050,797,2051],{"trials":2680,"activeCount":98},[],{"trials":2682,"activeCount":98},[],{"trials":2684,"activeCount":98},[],{"intervention":2051,"totalTrials":114,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[2693],{"nctId":2043,"briefTitle":2044,"status":142,"phases":2694,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":548,"conditions":2695,"interventions":2696},[88],[20],[2050,797,2051],{"trials":2698,"activeCount":98},[],{"trials":2700,"activeCount":98},[],{"trials":2702,"activeCount":98},[],{"intervention":2704,"totalTrials":114,"cells":2705},"MK-3475",{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2722,"PHASE4":2724,"NA":2726},{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[],{"trials":2711,"activeCount":98},[2712],{"nctId":2713,"briefTitle":2714,"status":142,"phases":2715,"primaryCompletion":2716,"completion":2716,"start":2717,"enrollment":302,"conditions":2718,"interventions":2720},"NCT02535247","Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma",[87,88],"2020-02-25","2016-01-05",[2719],"Lymphoma, T-Cell, Peripheral",[2704,2721],"Copanlisib",{"trials":2723,"activeCount":98},[],{"trials":2725,"activeCount":98},[],{"trials":2727,"activeCount":98},[],{"intervention":2721,"totalTrials":114,"cells":2729},{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2731,"activeCount":98},[],{"trials":2733,"activeCount":98},[],{"trials":2735,"activeCount":98},[2736],{"nctId":2713,"briefTitle":2714,"status":142,"phases":2737,"primaryCompletion":2716,"completion":2716,"start":2717,"enrollment":302,"conditions":2738,"interventions":2739},[87,88],[2719],[2704,2721],{"trials":2741,"activeCount":98},[],{"trials":2743,"activeCount":98},[],{"trials":2745,"activeCount":98},[],{"intervention":2747,"totalTrials":114,"cells":2748},"MLN8237 and Erlotinib",{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2753,"PHASE3":2766,"PHASE4":2768,"NA":2770},{"trials":2750,"activeCount":98},[],{"trials":2752,"activeCount":98},[],{"trials":2754,"activeCount":98},[2755],{"nctId":2756,"briefTitle":2757,"status":142,"phases":2758,"primaryCompletion":2759,"completion":2760,"start":2761,"enrollment":109,"conditions":2762,"interventions":2765},"NCT01471964","Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer",[87,88],"2017-02-07","2018-04-10","2011-10-20",[2763,2764],"Non-small Cell Lung Cancer Metastatic","Non-small Cell Lung Cancer Recurrent",[2747],{"trials":2767,"activeCount":98},[],{"trials":2769,"activeCount":98},[],{"trials":2771,"activeCount":98},[],{"intervention":237,"totalTrials":114,"cells":2773},{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2775,"activeCount":98},[],{"trials":2777,"activeCount":98},[],{"trials":2779,"activeCount":98},[2780],{"nctId":228,"briefTitle":229,"status":142,"phases":2781,"primaryCompletion":231,"completion":232,"start":233,"enrollment":147,"conditions":2782,"interventions":2783},[88],[235],[195,237],{"trials":2785,"activeCount":98},[],{"trials":2787,"activeCount":98},[],{"trials":2789,"activeCount":98},[],{"intervention":693,"totalTrials":114,"cells":2791},{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2796,"PHASE3":2802,"PHASE4":2804,"NA":2806},{"trials":2793,"activeCount":98},[],{"trials":2795,"activeCount":98},[],{"trials":2797,"activeCount":98},[2798],{"nctId":685,"briefTitle":686,"status":142,"phases":2799,"primaryCompletion":688,"completion":689,"start":690,"enrollment":21,"conditions":2800,"interventions":2801},[87,88],[408,395,410],[359,693],{"trials":2803,"activeCount":98},[],{"trials":2805,"activeCount":98},[],{"trials":2807,"activeCount":98},[],{"intervention":2809,"totalTrials":114,"cells":2810},"TAK-228",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2827,"PHASE4":2829,"NA":2831},{"trials":2812,"activeCount":98},[],{"trials":2814,"activeCount":98},[],{"trials":2816,"activeCount":98},[2817],{"nctId":2818,"briefTitle":2819,"status":142,"phases":2820,"primaryCompletion":2821,"completion":2822,"start":2823,"enrollment":32,"conditions":2824,"interventions":2826},"NCT02987959","Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas",[88],"2019-01-30","2020-07-24","2017-02-21",[2825],"Soft-tissue Sarcoma",[2809],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[],{"intervention":1006,"totalTrials":114,"cells":2834},{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2845,"PHASE4":2847,"NA":2849},{"trials":2836,"activeCount":98},[],{"trials":2838,"activeCount":98},[],{"trials":2840,"activeCount":98},[2841],{"nctId":998,"briefTitle":999,"status":130,"phases":2842,"primaryCompletion":1001,"completion":1002,"start":1003,"enrollment":26,"conditions":2843,"interventions":2844},[88],[17],[985,1006],{"trials":2846,"activeCount":98},[],{"trials":2848,"activeCount":98},[],{"trials":2850,"activeCount":98},[],{"intervention":2852,"totalTrials":114,"cells":2853},"chemotherapy",{"EARLY_PHASE1":2854,"PHASE1":2856,"PHASE2":2858,"PHASE3":2869,"PHASE4":2871,"NA":2873},{"trials":2855,"activeCount":98},[],{"trials":2857,"activeCount":98},[],{"trials":2859,"activeCount":98},[2860],{"nctId":2861,"briefTitle":2862,"status":130,"phases":2863,"primaryCompletion":2864,"completion":2864,"start":2865,"enrollment":94,"conditions":2866,"interventions":2867},"NCT00005848","R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",[88],"2007-05","2000-04",[23],[2852,2868],"tipifarnib",{"trials":2870,"activeCount":98},[],{"trials":2872,"activeCount":98},[],{"trials":2874,"activeCount":98},[],{"intervention":2868,"totalTrials":114,"cells":2876},{"EARLY_PHASE1":2877,"PHASE1":2879,"PHASE2":2881,"PHASE3":2887,"PHASE4":2889,"NA":2891},{"trials":2878,"activeCount":98},[],{"trials":2880,"activeCount":98},[],{"trials":2882,"activeCount":98},[2883],{"nctId":2861,"briefTitle":2862,"status":130,"phases":2884,"primaryCompletion":2864,"completion":2864,"start":2865,"enrollment":94,"conditions":2885,"interventions":2886},[88],[23],[2852,2868],{"trials":2888,"activeCount":98},[],{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[],{"intervention":2115,"totalTrials":114,"cells":2894},{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2905,"PHASE4":2907,"NA":2909},{"trials":2896,"activeCount":98},[],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[2901],{"nctId":2105,"briefTitle":2106,"status":142,"phases":2902,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":9,"conditions":2903,"interventions":2904},[88],[2112,2113],[2088,2115],{"trials":2906,"activeCount":98},[],{"trials":2908,"activeCount":98},[],{"trials":2910,"activeCount":98},[],{"intervention":2912,"totalTrials":114,"cells":2913},"Brigatinib",{"EARLY_PHASE1":2914,"PHASE1":2916,"PHASE2":2918,"PHASE3":2930,"PHASE4":2932,"NA":2934},{"trials":2915,"activeCount":98},[],{"trials":2917,"activeCount":98},[],{"trials":2919,"activeCount":98},[2920],{"nctId":2921,"briefTitle":2922,"status":181,"phases":2923,"primaryCompletion":2924,"completion":2925,"start":2926,"enrollment":98,"conditions":2927,"interventions":2929},"NCT03719898","Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma",[88],"2020-03-18","2020-06-16","2018-12-06",[2928],"Anaplastic Large Cell Lymphoma, ALK-Positive",[2912],{"trials":2931,"activeCount":98},[],{"trials":2933,"activeCount":98},[],{"trials":2935,"activeCount":98},[],{"intervention":2937,"totalTrials":114,"cells":2938},"Sotorasib, 960 mg, oral daily dose for 4 weeks",{"EARLY_PHASE1":2939,"PHASE1":2941,"PHASE2":2943,"PHASE3":2955,"PHASE4":2957,"NA":2959},{"trials":2940,"activeCount":98},[],{"trials":2942,"activeCount":98},[],{"trials":2944,"activeCount":98},[2945],{"nctId":2946,"briefTitle":2947,"status":181,"phases":2948,"primaryCompletion":2949,"completion":2950,"start":2951,"enrollment":98,"conditions":2952,"interventions":2954},"NCT05400577","Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC",[88],"2024-01-01","2024-02-01","2022-07-13",[2953],"Non-Small Cell Lung Cancer",[2937],{"trials":2956,"activeCount":98},[],{"trials":2958,"activeCount":98},[],{"trials":2960,"activeCount":98},[],{"intervention":2023,"totalTrials":114,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2964,"activeCount":98},[],{"trials":2966,"activeCount":98},[],{"trials":2968,"activeCount":98},[2969],{"nctId":2014,"briefTitle":2015,"status":142,"phases":2970,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":114,"conditions":2971,"interventions":2972},[87,88],[470,2021],[474,2023],{"trials":2974,"activeCount":98},[],{"trials":2976,"activeCount":98},[],{"trials":2978,"activeCount":98},[],{"intervention":2980,"totalTrials":114,"cells":2981},"Sorafenib",{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2996,"PHASE4":2998,"NA":3000},{"trials":2983,"activeCount":98},[],{"trials":2985,"activeCount":98},[],{"trials":2987,"activeCount":98},[2988],{"nctId":2989,"briefTitle":2990,"status":181,"phases":2991,"primaryCompletion":2992,"start":2993,"enrollment":98,"conditions":2994,"interventions":2995},"NCT00694291","Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer",[88],"2010-06","2008-06",[23],[2980],{"trials":2997,"activeCount":98},[],{"trials":2999,"activeCount":98},[],{"trials":3001,"activeCount":98},[],{"intervention":3003,"totalTrials":114,"cells":3004},"Octreotide",{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3021,"PHASE4":3023,"NA":3025},{"trials":3006,"activeCount":98},[],{"trials":3008,"activeCount":98},[],{"trials":3010,"activeCount":98},[3011],{"nctId":3012,"briefTitle":3013,"status":142,"phases":3014,"primaryCompletion":3015,"completion":3015,"start":3016,"enrollment":3017,"conditions":3018,"interventions":3020},"NCT03179995","Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy",[88],"2020-02-12","2017-07-07",23,[3019],"Major Liver Resection",[3003],{"trials":3022,"activeCount":98},[],{"trials":3024,"activeCount":98},[],{"trials":3026,"activeCount":98},[],{"intervention":1014,"totalTrials":114,"cells":3028},{"EARLY_PHASE1":3029,"PHASE1":3031,"PHASE2":3033,"PHASE3":3039,"PHASE4":3041,"NA":3043},{"trials":3030,"activeCount":98},[],{"trials":3032,"activeCount":98},[],{"trials":3034,"activeCount":98},[3035],{"nctId":1008,"briefTitle":1009,"status":142,"phases":3036,"primaryCompletion":860,"completion":732,"start":1011,"enrollment":826,"conditions":3037,"interventions":3038},[88],[31],[1014,985],{"trials":3040,"activeCount":98},[],{"trials":3042,"activeCount":98},[],{"trials":3044,"activeCount":98},[],{"intervention":3046,"totalTrials":114,"cells":3047},"Observation and Bicalutamide",{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3052,"PHASE3":3063,"PHASE4":3065,"NA":3067},{"trials":3049,"activeCount":98},[],{"trials":3051,"activeCount":98},[],{"trials":3053,"activeCount":98},[3054],{"nctId":3055,"briefTitle":3056,"status":130,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":1821,"enrollment":705,"conditions":3059,"interventions":3061},"NCT02614859","Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients",[88],"2020-01-24",[3060],"Cancer of Prostate",[3046,3062],"Metformin and Bicalutamide",{"trials":3064,"activeCount":98},[],{"trials":3066,"activeCount":98},[],{"trials":3068,"activeCount":98},[],{"intervention":3062,"totalTrials":114,"cells":3070},{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3081,"PHASE4":3083,"NA":3085},{"trials":3072,"activeCount":98},[],{"trials":3074,"activeCount":98},[],{"trials":3076,"activeCount":98},[3077],{"nctId":3055,"briefTitle":3056,"status":130,"phases":3078,"primaryCompletion":3058,"completion":3058,"start":1821,"enrollment":705,"conditions":3079,"interventions":3080},[88],[3060],[3046,3062],{"trials":3082,"activeCount":98},[],{"trials":3084,"activeCount":98},[],{"trials":3086,"activeCount":98},[],{"intervention":975,"totalTrials":114,"cells":3088},{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3090,"activeCount":98},[],{"trials":3092,"activeCount":98},[],{"trials":3094,"activeCount":98},[3095],{"nctId":965,"briefTitle":966,"status":181,"phases":3096,"enrollment":98,"conditions":3097,"interventions":3098},[88],[969,970,971,972,973],[933,499,975,976,977],{"trials":3100,"activeCount":98},[],{"trials":3102,"activeCount":98},[],{"trials":3104,"activeCount":98},[],{"intervention":976,"totalTrials":114,"cells":3106},{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3117,"PHASE4":3119,"NA":3121},{"trials":3108,"activeCount":98},[],{"trials":3110,"activeCount":98},[],{"trials":3112,"activeCount":98},[3113],{"nctId":965,"briefTitle":966,"status":181,"phases":3114,"enrollment":98,"conditions":3115,"interventions":3116},[88],[969,970,971,972,973],[933,499,975,976,977],{"trials":3118,"activeCount":98},[],{"trials":3120,"activeCount":98},[],{"trials":3122,"activeCount":98},[],{"intervention":977,"totalTrials":114,"cells":3124},{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3135,"PHASE4":3137,"NA":3139},{"trials":3126,"activeCount":98},[],{"trials":3128,"activeCount":98},[],{"trials":3130,"activeCount":98},[3131],{"nctId":965,"briefTitle":966,"status":181,"phases":3132,"enrollment":98,"conditions":3133,"interventions":3134},[88],[969,970,971,972,973],[933,499,975,976,977],{"trials":3136,"activeCount":98},[],{"trials":3138,"activeCount":98},[],{"trials":3140,"activeCount":98},[],{"intervention":3142,"totalTrials":114,"cells":3143},"single arm dose dense MVAC",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":98},[3150],{"nctId":3151,"briefTitle":3152,"status":130,"phases":3153,"primaryCompletion":3154,"completion":3155,"start":3156,"enrollment":3157,"conditions":3158,"interventions":3161},"NCT01031420","Dose Dense MVAC for Muscle Invasive Bladder Cancer",[88],"2013-07-19","2013-08-07","2009-12-07",54,[3159,3160],"Muscle Invasive Bladder Cancer","High Risk Urothelial Carcinoma of the Upper Urinary Tracts",[3142],{"trials":3163,"activeCount":98},[],{"trials":3165,"activeCount":98},[],{"trials":3167,"activeCount":98},[],{"intervention":3169,"totalTrials":114,"cells":3170},"Ixazomib",{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3172,"activeCount":98},[],{"trials":3174,"activeCount":98},[],{"trials":3176,"activeCount":98},[3177],{"nctId":3178,"briefTitle":3179,"status":142,"phases":3180,"primaryCompletion":3181,"completion":3181,"start":3182,"enrollment":147,"conditions":3183,"interventions":3185},"NCT02447887","Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)",[87,88],"2017-04-25","2015-08-14",[247,3184],"RCC",[3169,3186],"Pegylated IFN-alpha 2b",{"trials":3188,"activeCount":98},[],{"trials":3190,"activeCount":98},[],{"trials":3192,"activeCount":98},[],{"intervention":3186,"totalTrials":114,"cells":3194},{"EARLY_PHASE1":3195,"PHASE1":3197,"PHASE2":3199,"PHASE3":3205,"PHASE4":3207,"NA":3209},{"trials":3196,"activeCount":98},[],{"trials":3198,"activeCount":98},[],{"trials":3200,"activeCount":98},[3201],{"nctId":3178,"briefTitle":3179,"status":142,"phases":3202,"primaryCompletion":3181,"completion":3181,"start":3182,"enrollment":147,"conditions":3203,"interventions":3204},[87,88],[247,3184],[3169,3186],{"trials":3206,"activeCount":98},[],{"trials":3208,"activeCount":98},[],{"trials":3210,"activeCount":98},[],{"intervention":3212,"totalTrials":548,"cells":3213},"irinotecan-eluting beads",{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3246,"PHASE3":3248,"PHASE4":3250,"NA":3252},{"trials":3215,"activeCount":98},[],{"trials":3217,"activeCount":98},[3218,3235],{"nctId":3219,"briefTitle":3220,"status":142,"phases":3221,"primaryCompletion":3222,"completion":3223,"start":3224,"enrollment":548,"conditions":3225,"interventions":3234},"NCT02110953","Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver",[87],"2017-04-04","2017-08-16","2016-01-29",[3226,3227,3228,864,3229,3230,3231,876,3232,882,3233],"Liver Metastases","Mucinous Adenocarcinoma of the Colon","Mucinous Adenocarcinoma of the Rectum","Recurrent Rectal Cancer","Signet Ring Adenocarcinoma of the Colon","Signet Ring Adenocarcinoma of the Rectum","Stage IVA Rectal Cancer","Stage IVB Rectal Cancer",[3212],{"nctId":3236,"briefTitle":3237,"status":142,"phases":3238,"primaryCompletion":3239,"completion":3240,"start":3241,"enrollment":1884,"conditions":3242,"interventions":3245},"NCT01285102","Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer",[87],"2011-12","2013-01","2010-10",[3226,3227,3228,864,3229,3230,3231,3243,3244],"Stage IV Colon Cancer","Stage IV Rectal Cancer",[3212],{"trials":3247,"activeCount":98},[],{"trials":3249,"activeCount":98},[],{"trials":3251,"activeCount":98},[],{"trials":3253,"activeCount":98},[],{"intervention":3255,"totalTrials":548,"cells":3256},"vorinostat",{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3279,"PHASE3":3281,"PHASE4":3283,"NA":3285},{"trials":3258,"activeCount":98},[],{"trials":3260,"activeCount":98},[3261,3271],{"nctId":3262,"briefTitle":3263,"status":130,"phases":3264,"primaryCompletion":3265,"completion":3266,"start":3267,"enrollment":1033,"conditions":3268,"interventions":3270},"NCT01059552","Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)",[87],"2015-07-22","2019-10-21","2009-12-16",[3269],"Locally Advanced Non-small Cell Lung Cancer",[3255],{"nctId":3272,"briefTitle":3273,"status":130,"phases":3274,"primaryCompletion":3275,"completion":3275,"start":3241,"enrollment":562,"conditions":3276,"interventions":3277},"NCT01169532","Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma",[87],"2014-03",[28,25],[3278,3255],"ridaforolimus",{"trials":3280,"activeCount":98},[],{"trials":3282,"activeCount":98},[],{"trials":3284,"activeCount":98},[],{"trials":3286,"activeCount":98},[],{"intervention":3288,"totalTrials":114,"cells":3289},"QS21",{"EARLY_PHASE1":3290,"PHASE1":3292,"PHASE2":3302,"PHASE3":3304,"PHASE4":3306,"NA":3308},{"trials":3291,"activeCount":98},[],{"trials":3293,"activeCount":98},[3294],{"nctId":3295,"briefTitle":3296,"status":130,"phases":3297,"primaryCompletion":1003,"completion":1003,"start":3298,"enrollment":94,"conditions":3299,"interventions":3300},"NCT00006387","Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer",[87],"2000-10",[20,31],[3288,3301],"ras peptide cancer vaccine",{"trials":3303,"activeCount":98},[],{"trials":3305,"activeCount":98},[],{"trials":3307,"activeCount":98},[],{"trials":3309,"activeCount":98},[],{"intervention":3301,"totalTrials":114,"cells":3311},{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3320,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3313,"activeCount":98},[],{"trials":3315,"activeCount":98},[3316],{"nctId":3295,"briefTitle":3296,"status":130,"phases":3317,"primaryCompletion":1003,"completion":1003,"start":3298,"enrollment":94,"conditions":3318,"interventions":3319},[87],[20,31],[3288,3301],{"trials":3321,"activeCount":98},[],{"trials":3323,"activeCount":98},[],{"trials":3325,"activeCount":98},[],{"trials":3327,"activeCount":98},[],{"intervention":384,"totalTrials":114,"cells":3329},{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3338,"PHASE3":3340,"PHASE4":3342,"NA":3344},{"trials":3331,"activeCount":98},[],{"trials":3333,"activeCount":98},[3334],{"nctId":372,"briefTitle":373,"status":130,"phases":3335,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":3336,"interventions":3337},[87],[380,381,382],[384,385,125,319],{"trials":3339,"activeCount":98},[],{"trials":3341,"activeCount":98},[],{"trials":3343,"activeCount":98},[],{"trials":3345,"activeCount":98},[],{"intervention":385,"totalTrials":114,"cells":3347},{"EARLY_PHASE1":3348,"PHASE1":3350,"PHASE2":3356,"PHASE3":3358,"PHASE4":3360,"NA":3362},{"trials":3349,"activeCount":98},[],{"trials":3351,"activeCount":98},[3352],{"nctId":372,"briefTitle":373,"status":130,"phases":3353,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":3354,"interventions":3355},[87],[380,381,382],[384,385,125,319],{"trials":3357,"activeCount":98},[],{"trials":3359,"activeCount":98},[],{"trials":3361,"activeCount":98},[],{"trials":3363,"activeCount":98},[],{"intervention":398,"totalTrials":114,"cells":3365},{"EARLY_PHASE1":3366,"PHASE1":3368,"PHASE2":3374,"PHASE3":3376,"PHASE4":3378,"NA":3380},{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[3370],{"nctId":387,"briefTitle":388,"status":130,"phases":3371,"primaryCompletion":390,"completion":390,"start":391,"enrollment":135,"conditions":3372,"interventions":3373},[87],[393,394,395],[397,343,398],{"trials":3375,"activeCount":98},[],{"trials":3377,"activeCount":98},[],{"trials":3379,"activeCount":98},[],{"trials":3381,"activeCount":98},[],{"intervention":3383,"totalTrials":114,"cells":3384},"raltitrexed",{"EARLY_PHASE1":3385,"PHASE1":3387,"PHASE2":3398,"PHASE3":3400,"PHASE4":3402,"NA":3404},{"trials":3386,"activeCount":98},[],{"trials":3388,"activeCount":98},[3389],{"nctId":3390,"briefTitle":3391,"status":130,"phases":3392,"primaryCompletion":3298,"completion":3393,"start":3394,"enrollment":3395,"conditions":3396,"interventions":3397},"NCT00003109","Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors",[87],"2001-01","1997-12",39,[25],[764,3383],{"trials":3399,"activeCount":98},[],{"trials":3401,"activeCount":98},[],{"trials":3403,"activeCount":98},[],{"trials":3405,"activeCount":98},[],{"intervention":3407,"totalTrials":114,"cells":3408},"Romidepsin",{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3424,"PHASE3":3426,"PHASE4":3428,"NA":3430},{"trials":3410,"activeCount":98},[],{"trials":3412,"activeCount":98},[3413],{"nctId":3414,"briefTitle":3415,"status":130,"phases":3416,"primaryCompletion":3417,"completion":3418,"start":3419,"enrollment":562,"conditions":3420,"interventions":3422},"NCT02616965","A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma",[87],"2022-08-08","2024-01-31","2017-02-22",[3421],"Cutaneous T-cell Lymphoma (CTCL)",[3407,3423],"Brentuximab vedotin",{"trials":3425,"activeCount":98},[],{"trials":3427,"activeCount":98},[],{"trials":3429,"activeCount":98},[],{"trials":3431,"activeCount":98},[],{"intervention":3423,"totalTrials":114,"cells":3433},{"EARLY_PHASE1":3434,"PHASE1":3436,"PHASE2":3442,"PHASE3":3444,"PHASE4":3446,"NA":3448},{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[3438],{"nctId":3414,"briefTitle":3415,"status":130,"phases":3439,"primaryCompletion":3417,"completion":3418,"start":3419,"enrollment":562,"conditions":3440,"interventions":3441},[87],[3421],[3407,3423],{"trials":3443,"activeCount":98},[],{"trials":3445,"activeCount":98},[],{"trials":3447,"activeCount":98},[],{"trials":3449,"activeCount":98},[],{"intervention":412,"totalTrials":114,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3460,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":98},[3456],{"nctId":400,"briefTitle":401,"status":181,"phases":3457,"primaryCompletion":403,"completion":404,"enrollment":98,"conditions":3458,"interventions":3459},[87],[406,407,408,395,409,410],[412,343,359],{"trials":3461,"activeCount":98},[],{"trials":3463,"activeCount":98},[],{"trials":3465,"activeCount":98},[],{"trials":3467,"activeCount":98},[],{"intervention":3469,"totalTrials":114,"cells":3470},"Agent VM110 and laproscopic infra-red probe",{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3483,"PHASE3":3485,"PHASE4":3487,"NA":3489},{"trials":3472,"activeCount":98},[],{"trials":3474,"activeCount":98},[3475],{"nctId":3476,"briefTitle":3477,"status":142,"phases":3478,"primaryCompletion":3479,"completion":2076,"start":3480,"enrollment":114,"conditions":3481,"interventions":3482},"NCT03286062","VM110 in Detection of Microscopic Tumors: A Phase I Study",[87],"2019-07-10","2017-10-12",[497,31],[3469],{"trials":3484,"activeCount":98},[],{"trials":3486,"activeCount":98},[],{"trials":3488,"activeCount":98},[],{"trials":3490,"activeCount":98},[],{"intervention":3492,"totalTrials":114,"cells":3493},"interferon-gamma and nivolumab",{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3508,"PHASE3":3510,"PHASE4":3512,"NA":3514},{"trials":3495,"activeCount":98},[],{"trials":3497,"activeCount":98},[3498],{"nctId":3499,"briefTitle":3500,"status":130,"phases":3501,"primaryCompletion":3502,"completion":3502,"start":3503,"enrollment":3504,"conditions":3505,"interventions":3507},"NCT02614456","Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors",[87],"2019-06-12","2015-12-11",26,[3506],"Advanced Solid Tumors",[3492],{"trials":3509,"activeCount":98},[],{"trials":3511,"activeCount":98},[],{"trials":3513,"activeCount":98},[],{"trials":3515,"activeCount":98},[],{"intervention":780,"totalTrials":114,"cells":3517},{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3532},{"trials":3519,"activeCount":98},[],{"trials":3521,"activeCount":98},[3522],{"nctId":773,"briefTitle":774,"status":130,"phases":3523,"primaryCompletion":493,"completion":504,"start":776,"enrollment":32,"conditions":3524,"interventions":3525},[87],[778],[780,708],{"trials":3527,"activeCount":98},[],{"trials":3529,"activeCount":98},[],{"trials":3531,"activeCount":98},[],{"trials":3533,"activeCount":98},[],{"intervention":1037,"totalTrials":114,"cells":3535},{"EARLY_PHASE1":3536,"PHASE1":3538,"PHASE2":3544,"PHASE3":3546,"PHASE4":3548,"NA":3550},{"trials":3537,"activeCount":98},[],{"trials":3539,"activeCount":98},[3540],{"nctId":1028,"briefTitle":1029,"status":130,"phases":3541,"completion":1031,"start":1032,"enrollment":1033,"conditions":3542,"interventions":3543},[87],[25],[1036,1037],{"trials":3545,"activeCount":98},[],{"trials":3547,"activeCount":98},[],{"trials":3549,"activeCount":98},[],{"trials":3551,"activeCount":98},[],{"intervention":3278,"totalTrials":114,"cells":3553},{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3562,"PHASE3":3564,"PHASE4":3566,"NA":3568},{"trials":3555,"activeCount":98},[],{"trials":3557,"activeCount":98},[3558],{"nctId":3272,"briefTitle":3273,"status":130,"phases":3559,"primaryCompletion":3275,"completion":3275,"start":3241,"enrollment":562,"conditions":3560,"interventions":3561},[87],[28,25],[3278,3255],{"trials":3563,"activeCount":98},[],{"trials":3565,"activeCount":98},[],{"trials":3567,"activeCount":98},[],{"trials":3569,"activeCount":98},[],{"intervention":902,"totalTrials":114,"cells":3571},{"EARLY_PHASE1":3572,"PHASE1":3574,"PHASE2":3580,"PHASE3":3582,"PHASE4":3584,"NA":3586},{"trials":3573,"activeCount":98},[],{"trials":3575,"activeCount":98},[3576],{"nctId":895,"briefTitle":896,"status":181,"phases":3577,"primaryCompletion":898,"completion":898,"start":899,"enrollment":98,"conditions":3578,"interventions":3579},[87],[436,437,438,439,440,442,443,444,445,446,456],[397,460,902,903],{"trials":3581,"activeCount":98},[],{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[],{"trials":3587,"activeCount":98},[],{"intervention":3589,"totalTrials":114,"cells":3590},"ONC-201",{"EARLY_PHASE1":3591,"PHASE1":3593,"PHASE2":3605,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3592,"activeCount":98},[],{"trials":3594,"activeCount":98},[3595],{"nctId":3596,"briefTitle":3597,"status":130,"phases":3598,"primaryCompletion":133,"completion":3599,"start":3600,"enrollment":3601,"conditions":3602,"interventions":3604},"NCT02609230","A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma",[87],"2020-03-26","2015-11-05",33,[3506,3603],"Multiple Myeloma",[3589],{"trials":3606,"activeCount":98},[],{"trials":3608,"activeCount":98},[],{"trials":3610,"activeCount":98},[],{"trials":3612,"activeCount":98},[],{"intervention":3614,"totalTrials":114,"cells":3615},"5-ALA",{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3629,"PHASE3":3631,"PHASE4":3633,"NA":3635},{"trials":3617,"activeCount":98},[],{"trials":3619,"activeCount":98},[3620],{"nctId":3621,"briefTitle":3622,"status":2608,"phases":3623,"primaryCompletion":1135,"completion":1136,"start":3624,"enrollment":3625,"conditions":3626,"interventions":3628},"NCT04381806","Phase I Study in Advanced Malignancies With 5-ALA",[87],"2020-07-30",130,[3627],"Solid Tumor",[3614],{"trials":3630,"activeCount":98},[],{"trials":3632,"activeCount":98},[],{"trials":3634,"activeCount":98},[],{"trials":3636,"activeCount":98},[],{"intervention":3638,"totalTrials":114,"cells":3639},"MILs™ in Combination with Pembrolizumab",{"EARLY_PHASE1":3640,"PHASE1":3653,"PHASE2":3655,"PHASE3":3657,"PHASE4":3659,"NA":3661},{"trials":3641,"activeCount":98},[3642],{"nctId":3643,"briefTitle":3644,"status":181,"phases":3645,"primaryCompletion":3646,"completion":3647,"start":3648,"enrollment":98,"conditions":3649,"interventions":3652},"NCT04677361","Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab",[86],"2023-10","2024-10","2021-10",[3650,3651],"SCLC","NSCLC",[3638],{"trials":3654,"activeCount":98},[],{"trials":3656,"activeCount":98},[],{"trials":3658,"activeCount":98},[],{"trials":3660,"activeCount":98},[],{"trials":3662,"activeCount":98},[],{"intervention":3664,"totalTrials":114,"cells":3665},"Atorvastatin 20mg",{"EARLY_PHASE1":3666,"PHASE1":3678,"PHASE2":3680,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3667,"activeCount":98},[3668],{"nctId":3669,"briefTitle":3670,"status":130,"phases":3671,"primaryCompletion":3672,"completion":3672,"start":2585,"enrollment":3673,"conditions":3674,"interventions":3676},"NCT04379999","Atorvastatin ± Aspirin in Lynch Syndrome Syndrome",[86],"2025-08-04",43,[3675],"Lynch Syndrome",[3664,3677],"Atorvastatin 20mg AND Aspirin 325 mg",{"trials":3679,"activeCount":98},[],{"trials":3681,"activeCount":98},[],{"trials":3683,"activeCount":98},[],{"trials":3685,"activeCount":98},[],{"trials":3687,"activeCount":98},[],{"intervention":3677,"totalTrials":114,"cells":3689},{"EARLY_PHASE1":3690,"PHASE1":3696,"PHASE2":3698,"PHASE3":3700,"PHASE4":3702,"NA":3704},{"trials":3691,"activeCount":98},[3692],{"nctId":3669,"briefTitle":3670,"status":130,"phases":3693,"primaryCompletion":3672,"completion":3672,"start":2585,"enrollment":3673,"conditions":3694,"interventions":3695},[86],[3675],[3664,3677],{"trials":3697,"activeCount":98},[],{"trials":3699,"activeCount":98},[],{"trials":3701,"activeCount":98},[],{"trials":3703,"activeCount":98},[],{"trials":3705,"activeCount":98},[],{"intervention":3707,"totalTrials":114,"cells":3708},"Nivolumab, IV, 240 mg",{"EARLY_PHASE1":3709,"PHASE1":3720,"PHASE2":3722,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3710,"activeCount":98},[3711],{"nctId":3712,"briefTitle":3713,"status":130,"phases":3714,"primaryCompletion":3715,"completion":3715,"start":3716,"enrollment":15,"conditions":3717,"interventions":3719},"NCT03311958","Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance",[86],"2024-01-26","2018-05-15",[3718],"Diffuse Large B Cell Lymphoma",[3707],{"trials":3721,"activeCount":98},[],{"trials":3723,"activeCount":98},[],{"trials":3725,"activeCount":98},[],{"trials":3727,"activeCount":98},[],{"trials":3729,"activeCount":98},[],{"intervention":459,"totalTrials":32,"cells":3731},{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3740,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3733,"activeCount":98},[],{"trials":3735,"activeCount":98},[3736],{"nctId":856,"briefTitle":857,"status":130,"phases":3737,"primaryCompletion":859,"completion":859,"start":860,"enrollment":21,"conditions":3738,"interventions":3739},[87],[862,863,864,865,866,867,868,436,869,870,437,438,439,440,441,442,443,444,445,871,872,873,874,875,448,449,450,451,452,454,455,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,456],[397,459],{"trials":3741,"activeCount":98},[3742,3751,3755,3766],{"nctId":3743,"briefTitle":3744,"status":130,"phases":3745,"primaryCompletion":3746,"completion":2993,"start":3747,"enrollment":3748,"conditions":3749,"interventions":3750},"NCT00315185","Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer",[88],"2007-06","2004-12",53,[2142],[655],{"nctId":428,"briefTitle":429,"status":130,"phases":3752,"primaryCompletion":431,"completion":144,"start":432,"enrollment":433,"conditions":3753,"interventions":3754},[88],[435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457],[459,359,343,460],{"nctId":3756,"briefTitle":3757,"status":142,"phases":3758,"primaryCompletion":732,"completion":3759,"start":3760,"enrollment":3017,"conditions":3761,"interventions":3763},"NCT00321100","Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab",[88],"2013-12-18","2006-04-12",[3762],"Colorectal Neoplasms",[2144,459,3764,3765],"Oxaliplatin","Capecitabine",{"nctId":645,"briefTitle":646,"status":130,"phases":3767,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":3768,"interventions":3769},[88],[653],[655,319],{"trials":3771,"activeCount":98},[],{"trials":3773,"activeCount":98},[],{"trials":3775,"activeCount":98},[3776],{"nctId":3777,"briefTitle":3778,"status":142,"phases":3779,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":3783,"interventions":3785},"NCT01280643","Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",[91],"2013-07","2014-05","2010-03",[3784],"Metastatic Colorectal Cancer",[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],"leucovorin calcium","oxaliplatin","capecitabine","mutation analysis","gene expression analysis","nucleic acid sequencing","protein expression analysis","polymerase chain reaction","DNA analysis",{"intervention":3788,"totalTrials":1884,"cells":3796},{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3818,"PHASE3":3824,"PHASE4":3826,"NA":3828},{"trials":3798,"activeCount":98},[],{"trials":3800,"activeCount":98},[3801,3809],{"nctId":3802,"briefTitle":3803,"status":130,"phases":3804,"completion":3805,"start":3806,"conditions":3807,"interventions":3808},"NCT00084591","Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer",[87],"2007-02","2003-12",[20],[3788],{"nctId":3810,"briefTitle":3811,"status":130,"phases":3812,"primaryCompletion":3813,"completion":3814,"start":702,"enrollment":1138,"conditions":3815,"interventions":3817},"NCT00604409","Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer",[87],"2014-06","2015-01",[3816],"Metastatic Liver Cancer",[3788],{"trials":3819,"activeCount":98},[3820],{"nctId":3756,"briefTitle":3757,"status":142,"phases":3821,"primaryCompletion":732,"completion":3759,"start":3760,"enrollment":3017,"conditions":3822,"interventions":3823},[88],[3762],[2144,459,3764,3765],{"trials":3825,"activeCount":98},[],{"trials":3827,"activeCount":98},[],{"trials":3829,"activeCount":98},[3830],{"nctId":3777,"briefTitle":3778,"status":142,"phases":3831,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":3832,"interventions":3833},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":2144,"totalTrials":1884,"cells":3835},{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3878,"PHASE4":3880,"NA":3882},{"trials":3837,"activeCount":98},[],{"trials":3839,"activeCount":98},[],{"trials":3841,"activeCount":98},[3842,3846,3874],{"nctId":3756,"briefTitle":3757,"status":142,"phases":3843,"primaryCompletion":732,"completion":3759,"start":3760,"enrollment":3017,"conditions":3844,"interventions":3845},[88],[3762],[2144,459,3764,3765],{"nctId":3847,"briefTitle":3848,"status":130,"phases":3849,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":604,"conditions":3853,"interventions":3873},"NCT01212822","Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer",[88],"2014-10-24","2018-01-03","2011-04-27",[3854,381,3855,3856,3857,3858,3859,3860,3861,3862,3863,3864,3865,3866,3867,3868,3869,3870,3871,3872],"Adenocarcinoma of the Esophagus","Diffuse Adenocarcinoma of the Stomach","Intestinal Adenocarcinoma of the Stomach","Mixed Adenocarcinoma of the Stomach","Squamous Cell Carcinoma of the Esophagus","Stage IA Esophageal Cancer","Stage IA Gastric Cancer","Stage IB Esophageal Cancer","Stage IB Gastric Cancer","Stage IIA Esophageal Cancer","Stage IIA Gastric Cancer","Stage IIB Esophageal Cancer","Stage IIB Gastric Cancer","Stage IIIA Esophageal Cancer","Stage IIIA Gastric Cancer","Stage IIIB Esophageal Cancer","Stage IIIB Gastric Cancer","Stage IIIC Esophageal Cancer","Stage IIIC Gastric Cancer",[2144,3787,3786,736],{"nctId":2135,"briefTitle":2136,"status":130,"phases":3875,"primaryCompletion":2138,"completion":2139,"start":2140,"enrollment":826,"conditions":3876,"interventions":3877},[88],[2142],[2144,288],{"trials":3879,"activeCount":98},[],{"trials":3881,"activeCount":98},[],{"trials":3883,"activeCount":98},[3884],{"nctId":3777,"briefTitle":3778,"status":142,"phases":3885,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":3886,"interventions":3887},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":736,"totalTrials":1884,"cells":3889},{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3910,"PHASE4":3912,"NA":3914},{"trials":3891,"activeCount":98},[],{"trials":3893,"activeCount":98},[],{"trials":3895,"activeCount":98},[3896,3900,3906],{"nctId":3847,"briefTitle":3848,"status":130,"phases":3897,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":604,"conditions":3898,"interventions":3899},[88],[3854,381,3855,3856,3857,3858,3859,3860,3861,3862,3863,3864,3865,3866,3867,3868,3869,3870,3871,3872],[2144,3787,3786,736],{"nctId":3901,"briefTitle":3902,"status":130,"phases":3903,"primaryCompletion":365,"completion":2586,"start":354,"enrollment":3017,"conditions":3904,"interventions":3905},"NCT00021398","Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer",[88],[20],[736,3786],{"nctId":728,"briefTitle":729,"status":130,"phases":3907,"primaryCompletion":731,"completion":732,"start":733,"enrollment":135,"conditions":3908,"interventions":3909},[88],[423],[708,736,359],{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[],{"trials":3915,"activeCount":98},[3916],{"nctId":3777,"briefTitle":3778,"status":142,"phases":3917,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":3918,"interventions":3919},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":764,"totalTrials":1884,"cells":3921},{"EARLY_PHASE1":3922,"PHASE1":3924,"PHASE2":3938,"PHASE3":3940,"PHASE4":3942,"NA":3944},{"trials":3923,"activeCount":98},[],{"trials":3925,"activeCount":98},[3926,3930,3934],{"nctId":3390,"briefTitle":3391,"status":130,"phases":3927,"primaryCompletion":3298,"completion":3393,"start":3394,"enrollment":3395,"conditions":3928,"interventions":3929},[87],[25],[764,3383],{"nctId":758,"briefTitle":759,"status":130,"phases":3931,"completion":761,"start":494,"conditions":3932,"interventions":3933},[87],[14],[708,764],{"nctId":766,"briefTitle":767,"status":130,"phases":3935,"primaryCompletion":713,"completion":713,"start":769,"conditions":3936,"interventions":3937},[87],[14],[708,764],{"trials":3939,"activeCount":98},[],{"trials":3941,"activeCount":98},[],{"trials":3943,"activeCount":98},[],{"trials":3945,"activeCount":98},[3946],{"nctId":3777,"briefTitle":3778,"status":142,"phases":3947,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":3948,"interventions":3949},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":3787,"totalTrials":147,"cells":3951},{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3966,"PHASE4":3968,"NA":3970},{"trials":3953,"activeCount":98},[],{"trials":3955,"activeCount":98},[],{"trials":3957,"activeCount":98},[3958,3962],{"nctId":3756,"briefTitle":3757,"status":142,"phases":3959,"primaryCompletion":732,"completion":3759,"start":3760,"enrollment":3017,"conditions":3960,"interventions":3961},[88],[3762],[2144,459,3764,3765],{"nctId":3847,"briefTitle":3848,"status":130,"phases":3963,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":604,"conditions":3964,"interventions":3965},[88],[3854,381,3855,3856,3857,3858,3859,3860,3861,3862,3863,3864,3865,3866,3867,3868,3869,3870,3871,3872],[2144,3787,3786,736],{"trials":3967,"activeCount":98},[],{"trials":3969,"activeCount":98},[],{"trials":3971,"activeCount":98},[3972],{"nctId":3777,"briefTitle":3778,"status":142,"phases":3973,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":3974,"interventions":3975},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":3786,"totalTrials":147,"cells":3977},{"EARLY_PHASE1":3978,"PHASE1":3980,"PHASE2":3982,"PHASE3":3992,"PHASE4":3994,"NA":3996},{"trials":3979,"activeCount":98},[],{"trials":3981,"activeCount":98},[],{"trials":3983,"activeCount":98},[3984,3988],{"nctId":3847,"briefTitle":3848,"status":130,"phases":3985,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":604,"conditions":3986,"interventions":3987},[88],[3854,381,3855,3856,3857,3858,3859,3860,3861,3862,3863,3864,3865,3866,3867,3868,3869,3870,3871,3872],[2144,3787,3786,736],{"nctId":3901,"briefTitle":3902,"status":130,"phases":3989,"primaryCompletion":365,"completion":2586,"start":354,"enrollment":3017,"conditions":3990,"interventions":3991},[88],[20],[736,3786],{"trials":3993,"activeCount":98},[],{"trials":3995,"activeCount":98},[],{"trials":3997,"activeCount":98},[3998],{"nctId":3777,"briefTitle":3778,"status":142,"phases":3999,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":4000,"interventions":4001},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":4003,"totalTrials":548,"cells":4004},"targeted therapy",{"EARLY_PHASE1":4005,"PHASE1":4007,"PHASE2":4009,"PHASE3":4011,"PHASE4":4013,"NA":4015},{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[],{"trials":4010,"activeCount":98},[],{"trials":4012,"activeCount":98},[],{"trials":4014,"activeCount":98},[],{"trials":4016,"activeCount":98},[4017,4030],{"nctId":4018,"briefTitle":4019,"status":142,"phases":4020,"primaryCompletion":4021,"completion":4021,"start":4022,"enrollment":114,"conditions":4023,"interventions":4029},"NCT02132884","Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer",[91],"2016-08","2015-03",[4024,4025,4026,4027,4028],"Malignant Pericardial Effusion","Malignant Pleural Effusion","Recurrent Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer",[4003],{"nctId":4031,"briefTitle":4032,"status":130,"phases":4033,"primaryCompletion":4034,"completion":4034,"start":4035,"enrollment":1634,"conditions":4036,"interventions":4038},"NCT02132845","Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer",[91],"2018-05-10","2016-03-17",[4037],"Malignant Neoplasm",[4003],{"intervention":903,"totalTrials":548,"cells":4040},{"EARLY_PHASE1":4041,"PHASE1":4043,"PHASE2":4049,"PHASE3":4051,"PHASE4":4053,"NA":4055},{"trials":4042,"activeCount":98},[],{"trials":4044,"activeCount":98},[4045],{"nctId":895,"briefTitle":896,"status":181,"phases":4046,"primaryCompletion":898,"completion":898,"start":899,"enrollment":98,"conditions":4047,"interventions":4048},[87],[436,437,438,439,440,442,443,444,445,446,456],[397,460,902,903],{"trials":4050,"activeCount":98},[],{"trials":4052,"activeCount":98},[],{"trials":4054,"activeCount":98},[],{"trials":4056,"activeCount":98},[4057],{"nctId":4058,"briefTitle":4059,"status":142,"phases":4060,"primaryCompletion":3275,"completion":3275,"start":1002,"enrollment":548,"conditions":4061,"interventions":4063},"NCT00700778","Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations",[91],[4062,17],"BRCA1 Mutation",[4064,903],"recombinant human chorionic gonadotropin",{"intervention":4066,"totalTrials":548,"cells":4067},"celecoxib",{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4072,"PHASE3":4082,"PHASE4":4084,"NA":4086},{"trials":4069,"activeCount":98},[],{"trials":4071,"activeCount":98},[],{"trials":4073,"activeCount":98},[4074],{"nctId":4075,"briefTitle":4076,"status":130,"phases":4077,"primaryCompletion":4078,"completion":4078,"start":724,"conditions":4079,"interventions":4081},"NCT00101335","Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia",[88],"2005-01",[304,4080],"Precancerous Condition",[4066],{"trials":4083,"activeCount":98},[],{"trials":4085,"activeCount":98},[],{"trials":4087,"activeCount":98},[4088],{"nctId":4089,"briefTitle":4090,"status":181,"phases":4091,"primaryCompletion":702,"completion":702,"start":4092,"enrollment":98,"conditions":4093,"interventions":4094},"NCT00084578","Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder",[91],"2004-03",[1713],[4066,4095],"rosiglitazone maleate",{"intervention":3792,"totalTrials":548,"cells":4097},{"EARLY_PHASE1":4098,"PHASE1":4100,"PHASE2":4102,"PHASE3":4104,"PHASE4":4106,"NA":4108},{"trials":4099,"activeCount":98},[],{"trials":4101,"activeCount":98},[],{"trials":4103,"activeCount":98},[],{"trials":4105,"activeCount":98},[],{"trials":4107,"activeCount":98},[],{"trials":4109,"activeCount":98},[4110,4114],{"nctId":3777,"briefTitle":3778,"status":142,"phases":4111,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":4112,"interventions":4113},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"nctId":4115,"briefTitle":4116,"status":130,"phases":4117,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":1372,"conditions":4121,"interventions":4122},"NCT00900016","Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery",[],"2013-12","2017-06-23","2007-08",[31],[3792,4123],"western blotting",{"intervention":4064,"totalTrials":114,"cells":4125},{"EARLY_PHASE1":4126,"PHASE1":4128,"PHASE2":4130,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4127,"activeCount":98},[],{"trials":4129,"activeCount":98},[],{"trials":4131,"activeCount":98},[],{"trials":4133,"activeCount":98},[],{"trials":4135,"activeCount":98},[],{"trials":4137,"activeCount":98},[4138],{"nctId":4058,"briefTitle":4059,"status":142,"phases":4139,"primaryCompletion":3275,"completion":3275,"start":1002,"enrollment":548,"conditions":4140,"interventions":4141},[91],[4062,17],[4064,903],{"intervention":4095,"totalTrials":114,"cells":4143},{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4145,"activeCount":98},[],{"trials":4147,"activeCount":98},[],{"trials":4149,"activeCount":98},[],{"trials":4151,"activeCount":98},[],{"trials":4153,"activeCount":98},[],{"trials":4155,"activeCount":98},[4156],{"nctId":4089,"briefTitle":4090,"status":181,"phases":4157,"primaryCompletion":702,"completion":702,"start":4092,"enrollment":98,"conditions":4158,"interventions":4159},[91],[1713],[4066,4095],{"intervention":3789,"totalTrials":114,"cells":4161},{"EARLY_PHASE1":4162,"PHASE1":4164,"PHASE2":4166,"PHASE3":4168,"PHASE4":4170,"NA":4172},{"trials":4163,"activeCount":98},[],{"trials":4165,"activeCount":98},[],{"trials":4167,"activeCount":98},[],{"trials":4169,"activeCount":98},[],{"trials":4171,"activeCount":98},[],{"trials":4173,"activeCount":98},[4174],{"nctId":3777,"briefTitle":3778,"status":142,"phases":4175,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":4176,"interventions":4177},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":3790,"totalTrials":114,"cells":4179},{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4181,"activeCount":98},[],{"trials":4183,"activeCount":98},[],{"trials":4185,"activeCount":98},[],{"trials":4187,"activeCount":98},[],{"trials":4189,"activeCount":98},[],{"trials":4191,"activeCount":98},[4192],{"nctId":3777,"briefTitle":3778,"status":142,"phases":4193,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":4194,"interventions":4195},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":3791,"totalTrials":114,"cells":4197},{"EARLY_PHASE1":4198,"PHASE1":4200,"PHASE2":4202,"PHASE3":4204,"PHASE4":4206,"NA":4208},{"trials":4199,"activeCount":98},[],{"trials":4201,"activeCount":98},[],{"trials":4203,"activeCount":98},[],{"trials":4205,"activeCount":98},[],{"trials":4207,"activeCount":98},[],{"trials":4209,"activeCount":98},[4210],{"nctId":3777,"briefTitle":3778,"status":142,"phases":4211,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":4212,"interventions":4213},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":3793,"totalTrials":114,"cells":4215},{"EARLY_PHASE1":4216,"PHASE1":4218,"PHASE2":4220,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4217,"activeCount":98},[],{"trials":4219,"activeCount":98},[],{"trials":4221,"activeCount":98},[],{"trials":4223,"activeCount":98},[],{"trials":4225,"activeCount":98},[],{"trials":4227,"activeCount":98},[4228],{"nctId":3777,"briefTitle":3778,"status":142,"phases":4229,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":4230,"interventions":4231},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":3794,"totalTrials":114,"cells":4233},{"EARLY_PHASE1":4234,"PHASE1":4236,"PHASE2":4238,"PHASE3":4240,"PHASE4":4242,"NA":4244},{"trials":4235,"activeCount":98},[],{"trials":4237,"activeCount":98},[],{"trials":4239,"activeCount":98},[],{"trials":4241,"activeCount":98},[],{"trials":4243,"activeCount":98},[],{"trials":4245,"activeCount":98},[4246],{"nctId":3777,"briefTitle":3778,"status":142,"phases":4247,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":147,"conditions":4248,"interventions":4249},[91],[3784],[736,3786,3787,764,2144,459,3788,3789,3790,3791,3792,3793,3794],{"intervention":4123,"totalTrials":114,"cells":4251},{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4258,"PHASE4":4260,"NA":4262},{"trials":4253,"activeCount":98},[],{"trials":4255,"activeCount":98},[],{"trials":4257,"activeCount":98},[],{"trials":4259,"activeCount":98},[],{"trials":4261,"activeCount":98},[],{"trials":4263,"activeCount":98},[4264],{"nctId":4115,"briefTitle":4116,"status":130,"phases":4265,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":1372,"conditions":4266,"interventions":4267},[],[31],[3792,4123]]